10-Q

0000950170-24-059081.txt : 20240514 0000950170-24-059081.hdr.sgml : 20240514 20240514072828 ACCESSION NUMBER: 0000950170-24-059081 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 24941449 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 10-Q 1 inkt-20240331.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission File Number: 001-40908

MiNK Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware	82-2142067
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
149 Fifth Avenue Suite 500 New York, NY	10010
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 212-994-8250

Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading
Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.00001 per share

    INKT

    Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 10, 2024, the registrant had 34,727,639 shares of common stock, $0.00001 par value per share, outstanding.

Table of Contents


		Page

PART I.	FINANCIAL INFORMATION	1

Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023	1
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023	2
	Condensed Consolidated Statements of Stockholders’ Deficit for the three months ended March 31, 2024 and 2023	3
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023	5
	Notes to Unaudited Interim Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17
Item 4.	Controls and Procedures	17

PART II.	OTHER INFORMATION	18

Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 5.	Other Information	18
Item 6.	Exhibits	19
	Signatures	20

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

MINK THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	March 31, 2024			December 31, 2023
ASSETS
Cash and cash equivalents	$	5,817,080		$	3,367,229
Prepaid expenses		59,394			53,111
Other current assets		122,477			177,964
Total current assets		5,998,951			3,598,304
Equipment, net of accumulated depreciation of $545,095 and $495,638 at March 31, 2024 and December 31, 2023, respectively		894,992			953,977
Total assets	$	6,893,943		$	4,552,281
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts payable	$	3,486,999		$	3,911,973
Accrued liabilities		5,282,707			5,037,361
Other current liabilities		2,338,554			2,453,251
Total current liabilities		11,108,260			11,402,585
Related party note		4,211,566			—
Other long-term liabilities		31,600			48,072
Due to related parties		11,841,724			11,157,073
Commitments and contingencies
STOCKHOLDERS’ DEFICIT
Common stock, par value $0.00001 per share; 150,000,000 shares authorized; 34,699,056 and 34,599,119 shares issued at March 31, 2024 and December 31, 2023, respectively		347			346
Additional paid-in capital		117,296,454			115,772,085
Accumulated other comprehensive loss		(385,780	)		(430,947	)
Accumulated deficit		(137,210,228	)		(133,396,933	)
Total stockholders’ deficit		(20,299,207	)		(18,055,449	)
Total liabilities and stockholders’ deficit	$	6,893,943		$	4,552,281

See accompanying notes to unaudited condensed consolidated financial statements.

MINK THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)


	Three Months Ended March 31,
	2024			2023
Operating expenses:
Research and development	$	2,549,482		$	4,193,562
General and administrative		1,280,432			1,660,534
Operating loss		(3,829,914	)		(5,854,096	)
Other income, net:
Interest income, net		16,619			168,055
Net loss	$	(3,813,295	)	$	(5,686,041	)
Per common share data:
Basic and diluted net loss per common share	$	(0.11	)	$	(0.17	)
Weighted average number of common shares outstanding		34,642,915			33,966,921
Other comprehensive income (loss):
Foreign currency translation gain (loss)	$	45,167		$	(81,335	)
Comprehensive loss	$	(3,768,128	)	$	(5,767,376	)

See accompanying notes to unaudited condensed consolidated financial statements.

MINK THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(Unaudited)


	Common Stock							Treasury Stock				Accumulated
	Number of Shares		Par Value		Additional Paid-In Capital			Number of Shares		Par Value		Other Comprehensive Income (Loss)			Accumulated Deficit			Total
Balance at December 31, 2023		34,599,119	$	346	$	115,772,085			—	$	—	$	(430,947	)	$	(133,396,933	)		(18,055,449	)
Net loss		—		—		—			—		—		—			(3,813,295	)		(3,813,295	)
Other comprehensive income		—		—		—			—		—		45,167			—			45,167
Issuance of related party note (Note 8)		—		—		792,878			—		—		—			—			792,878
Exercise of stock options and employee share purchases		22,851		—		6,896			—		—		—			—			6,896
Vesting of nonvested shares		77,086		1		(1	)		—		—		—			—			—
Grant and recognition of stock options		—		—		697,563			—		—		—			—			697,563
Recognition of parent stock options		—		—		27,033			—		—		—			—			27,033
Balance at March 31, 2024		34,699,056	$	347	$	117,296,454			—	$	—	$	(385,780	)	$	(137,210,228	)	$	(20,299,207	)

MINK THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(Unaudited)


	Common Stock								Treasury Stock						Accumulated
	Number of Shares			Par Value			Additional Paid-In Capital		Number of Shares			Par Value			Other Comprehensive Income (Loss)			Accumulated Deficit			Total
Balance at December 31, 2022		33,856,428		$	339		$	110,829,900		—		$	—		$	(292,468	)	$	(110,939,074	)	$	(401,303	)
Net loss		—			—			—		—			—			—			(5,686,041	)		(5,686,041	)
Other comprehensive loss		—			—			—		—			—			(81,335	)		—			(81,335	)
Exercise of stock options and employee share purchases		99,555			1			45,495		—			—			—			—			45,496
Vesting of nonvested shares		30,413			—			—		—			—			—			—			—
Grant and recognition of stock options		—			—			887,811		—			—			—			—			887,811
Recognition of parent stock options		—			—			33,328		—			—			—			—			33,328
Issuance of shares for employee bonuses		476,804			5			726,260		(163,759	)		(379,921	)		—			—			346,344
Retirement of treasury shares		(163,759	)		(2	)		—		163,759			379,921			—			—			379,919
Balance at March 31, 2023		34,299,441		$	343		$	112,522,794		—		$	—		$	(373,803	)	$	(116,625,115	)	$	(4,475,781	)

See accompanying notes to unaudited condensed consolidated financial statements.

MINK THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Three Months Ended March 31,
	2024			2023
Cash flows from operating activities:
Net loss	$	(3,813,295	)	$	(5,686,041	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		53,831			45,686
Share-based compensation		592,006			921,139
Interest accrued on related party note		4,444			—
Changes in operating assets and liabilities:
Prepaid expenses		(6,349	)		(10,010	)
Accounts payable		(424,439	)		153,919
Accrued liabilities and other current liabilities		324,451			(549,527	)
Other operating assets and liabilities		727,144			758,424
Net cash used in operating activities		(2,542,207	)		(4,366,410	)
Cash flows from investing activities:
Purchases of plant and equipment		—			(13,500	)
Net cash used in investing activities		—			(13,500	)
Cash flows from financing activities:
Proceeds from issuance of related party note		5,000,000			—
Proceeds from employee stock purchases and option exercises		6,896			45,496
Purchase of treasury shares to satisfy tax withholdings		—			(379,921	)
Net cash provided by (used in) financing activities		5,006,896			(334,425	)
Effect of exchange rate changes on cash		(14,838	)		(29,340	)
Net increase (decrease) in cash and cash equivalents		2,449,851			(4,743,675	)
Cash and cash equivalents, beginning of period		3,367,229			19,635,725
Cash and cash equivalents, end of period	$	5,817,080		$	14,892,050
Supplemental cash flow information:
Cash paid for interest	$	5,116		$	9,961
Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities	$	—		$	23,042
Issuance of stock options for payment of certain employee bonuses		132,590			—
Issuance of related party note (Note 8)		792,878			—
Issuance of common stock, $0.00001 par value, for payment of certain employee bonuses		—			726,263

See accompanying notes to unaudited condensed consolidated financial statements.

MINK THERAPEUTICS, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Business and Liquidity

MiNK Therapeutics, Inc. (“MiNK” or the “Company”) is a clinical stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (“iNKT”) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. MiNK’s proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, the Company believes that its approach represents a highly versatile application for therapeutic development in cancer and immune diseases. MiNK is leveraging its platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells.

Since its inception in 2017, MiNK has incurred losses and expects to continue incurring operating losses and negative cash flows in the future until it is able to generate sales and profits. As of March 31, 2024, MiNK had an accumulated deficit of $137.2 million and cash and cash equivalents of $5.8 million.

MiNK believes that its cash and cash equivalents balance, along with additional funding of $5.8 million received after quarter end (see Note 11), will be sufficient to satisfy its liquidity requirements for more than one year from when these financial statements were issued. Because MiNK is dependent on its parent, Agenus Inc. ("Agenus") for certain services and deferral of related payments as discussed in Note 7, and Agenus has recently disclosed the existence of a substantial doubt about its ability to continue as a going concern, in accordance with the relevant accounting guidance, the Company is also required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q. To support its liquidity requirements beyond one year from when these financial statements are issued the Company will require additional funding. The financial statements have been prepared on a basis that assumes MiNK will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Management continually monitors MiNK's liquidity position and adjusts spending as needed in order to preserve liquidity. Potential sources of additional funding for the Company include: (1) seeking strategic partnerships and collaborations, as well as out-licensing opportunities, for the Company's portfolio programs and product candidates, (2) exploring avenues for securing non-dilutive financing, such as grants and collaborations to strengthen the Company's balance sheet, and (3) potential of equity or debt financing options. If additional funding is not obtained through these sources, Agenus has indicated a willingness to loan MiNK additional funds to finance its operations.

MiNK’s product candidates are in various stages of development and additional expenditures will be required if the Company starts new trials, encounters delays in its programs, applies for regulatory approvals, continues development of its technologies, expands its operations, and/or brings its product candidates to market. The eventual total cost of each clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, and number of patients. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive, and uncertain. Because all of the Company’s programs are at an early stage of clinical development, the Company is unable to reliably estimate the cost of completing its research and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence.

(2) Significant Accounting Policies

Fair Value Option

Under the Fair Value Option subsection of ASC Subtopic 825-10, Financial Instruments – Overall, the Company has the irrevocable option to report most financial assets and liabilities at fair value on an instrument-by-instrument basis with changes in fair value reported in earnings. The Company has elected to report the related party note it issued to Agenus on February 12, 2024 (the “Note”) at fair value. The fair value of the Note is determined on a scenario based present value methodology. The outstanding principal amount of the Note was $5.0 million at March 31, 2024.

Other Policies

The Company’s remaining significant accounting policies are disclosed in the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and

Exchange Commission (“SEC”) on March 21, 2024. Since the date of those financial statements there have been no changes, other than the fair value option policy defined above, to the Company’s significant accounting policies.

Financial Statement Preparation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of the Company’s management, the condensed consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. All significant intercompany transactions and accounts have been eliminated in consolidation. Operating results for the three months ended March 31, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.

For the Company’s foreign subsidiaries, the local currency is the functional currency. Assets and liabilities of its foreign subsidiaries are translated into U.S. dollars using rates in effect at the balance sheet date while expenses are translated into U.S. dollars using average exchange rates during the period. The cumulative translation adjustment resulting from changes in exchange rates are included in the condensed consolidated balance sheets as a component of accumulated other comprehensive income (loss) in total stockholders’ deficit.

(3) Net Loss Per Share

Basic loss per common share is calculated by dividing the net loss by the weighted average number of common shares outstanding. Diluted loss per common share is calculated by dividing net loss by the weighted average number of common shares outstanding plus the dilutive effect of outstanding instruments such as stock options. Because the Company reported a net loss for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of March 31, 2024 and 2023, as they would be anti-dilutive:


	Three Months Ended March 31,
	2024		2023
Stock options		8,246,769		6,720,366
Non-vested shares		781,893		885,756

(4) Cash and Cash Equivalents

Cash equivalents consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024				December 31, 2023
	Cost		Estimated Fair Value		Cost		Estimated Fair Value
Institutional money market funds	$	5,424	$	5,424	$	2,899	$	2,899

(5) Accrued and Other Current Liabilities

Accrued liabilities consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024		December 31, 2023
Payroll	$	2,067	$	1,831
Professional fees		492		398
Research services		294		302
Contract manufacturing costs		2,430		2,430
Other		—		76
Total	$	5,283	$	5,037

Other current liabilities of $2.3 million as of both March 31, 2024 and December 31, 2023, represent the advance received under the Company’s research and development agreement with the Belgium Walloon Region Government (“Walloon Region”). In 2022, the Company received notice that the Walloon Region had obtained a default judgment seeking repayment of approximately $2.3 million of the advance based upon the Company allegedly not providing required notification that research and operations in the region were discontinued.

(6) Share-based Compensation Plans

The Company primarily uses the Black-Scholes option pricing model to value options granted to employees and non-employees, as well as options granted to members of the Company’s Board of Directors. All stock option grants have 10-year terms and generally vest ratably over a 3 or 4-year period.

A summary of option activity for the three-month period ended March 31, 2024 is presented below:


	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at December 31, 2023		6,945,716		$	2.03
Granted		1,346,997			0.87
Exercised		(15,469	)		0.01
Forfeited		(30,262	)		1.72
Expired		(213	)		2.28
Outstanding at March 31, 2024		8,246,769		$	1.85		7.51	$	1,926,229
Vested or expected to vest at March 31, 2024		8,246,769		$	1.85		7.51	$	1,926,229
Exercisable at March 31, 2024		4,534,989		$	1.58		6.55	$	1,875,043

The weighted average grant-date fair values of options granted during the three months ended March 31, 2024 and 2023 were $0.69 and $1.74, respectively. During the three months ended March 31, 2024 and 2023, all options were granted with exercise prices equal to the market value of the underlying shares of common stock on the grant date.

As of March 31, 2024, there was $3.0 million of unrecognized share-based compensation expense related to stock options granted to employees, consultants and directors which, if all milestones are achieved on outstanding performance based awards, will be recognized over a weighted average period of 1.8 years. For awards with performance conditions, expense is recognized if the underlying performance conditions are deemed probable of achievement.

A summary of non-vested stock activity for the three-month period ended March 31, 2024 is presented below:


	Nonvested Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2023		789,503		$	1.18
Granted		69,476			0.95
Vested		(77,086	)		1.04
Forfeited		—			—
Outstanding at March 31, 2024		781,893		$	1.17

As of March 31, 2024, there was $0.8 million of unrecognized share-based compensation expense related to these non-vested shares which will be recognized over a weighted average period of 4.4 years.

During the three months ended March 31, 2024, 7,382 shares were issued under the 2021 Employee Stock Purchase Plan, 15,469 shares were issued as a result of stock option exercises and 77,086 shares were issued as a result of the vesting of non-vested stock.

Stock based compensation expense also includes expense related to awards to employees of the Company from the Agenus 2019 Equity Incentive Plan. The impact on the Company’s results of operations from share-based compensation for the three months ended March 31, 2024 and 2023, was as follows (in thousands):


	Three Months Ended March 31,
	2024		2023
Research and development	$	122	$	141
General and administrative		603		780
Total share-based compensation expense	$	725	$	921

(7) Related Party Transactions

Until the completion of its Initial Public Offering (“IPO”), the Company relied on Agenus for all of its working capital requirements. For the periods presented, certain of the Company’s operations were fully integrated with Agenus, including, but not limited to, corporate functions such as finance, human resources, information technology and certain legal functions. The Company’s consolidated financial statements reflect all costs of doing business related to these operations.

In September 2021, the Company entered into an Intellectual Property Assignment and License Agreement with Agenus (the “New Assignment and License Agreement”), upon which the prior intercompany agreement between Agenus and MiNK was terminated. Pursuant to the New Assignment and License Agreement, Agenus assigned to the Company certain patent rights and know-how related to its iNKT cell platform, product candidates and other patents and know-how related to its business. In addition to the patent rights assigned to the Company by Agenus, the Company also received an exclusive, royalty-free, sublicensable license to research, develop, manufacture and commercialize certain licensed technology in the field. The New Assignment and License Agreement further provides for the Company to grant Agenus a field-limited, non-exclusive, royalty-free license under the assigned patent rights, subject to MiNK’s discretion and provided such access would not reasonably result in a disruption of planned MiNK activities. Agenus has also agreed to provide the Company with Agenus’ biological material upon written request in order for the Company to use such material in its development activities of a combination therapy. Agenus may withhold the transfer of biological material, including, but not limited to, checkpoint modulating antibodies, for various reasons, including if such transfer would reasonably result in a disruption of planned Agenus activities. For any materials Agenus does share with the Company, the parties have agreed to enter into a separate agreement governing the transfer and providing for joint ownership of the data. Agenus has agreed that during the full term of the New Assignment and License Agreement, and for three years thereafter, it will not develop, manufacture or commercialize an iNKT cell therapy, directly or indirectly by transferring such technology. The Company may terminate the New Assignment and License Agreement without cause upon 90 days’ prior written notice to Agenus. Either party may terminate if there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice.

Effective April 1, 2022, the Company entered into an Amended and Restated Intercompany Services Agreement (the “New Intercompany Agreement”) with Agenus, which amended and restated the Intercompany General & Administrative Agreement between the Company and Agenus dated September 10, 2021 (the “Prior Intercompany Agreement”). Under the New Intercompany

Agreement, Agenus provides the Company with certain general and administrative support, including, without limitation, financial, facilities management, human resources and information technology administrative support (the “Agenus Services”), and the Company and Agenus provide each other with certain research and development services (the “R&D Services”) and other support services, including legal and regulatory support (the “Shared Services”). The Company is required to pay 10% of Agenus’ costs related to the Agenus Services, and the costs of R&D Services are based upon pass-through costs related to such services plus an allocation of the costs of the employees performing the services. No payment will be due from either party for the Shared Services, provided that the services provided by each party are proportional in scope and volume. The Company is also entitled to use Agenus’ business offices and laboratory space and equipment in exchange for the Company contributing a proportionate payment for the use of such facilities and equipment, and the Company will be covered by certain Agenus insurance policies, subject to certain conditions, including the Company paying the cost of such coverage. Either party may terminate the New Intercompany Agreement upon 60 days’ prior written notice and individual services upon 30 days’ prior written notice.

Allocated Agenus services primarily include payroll related expenses, facility costs, insurance and stock-based compensation, and are included in the accompanying financial statements based on certain estimates and allocations described above. Under the Prior Intercompany Agreement, the allocation methods primarily included time devoted to activities and headcount-based allocations. Agenus business services and occupancy costs were allocated to the Company based on the Company’s headcount as a percentage of Agenus’ and the Company was required to pay 105% of Agenus’ costs for these business services and occupancy costs. Research services were charged between the entities based on hours recorded by Agenus employees as time spent on specific projects, applied to hourly wage rates, and the Company paid 110% of Agenus’ costs for these research services. As such, these allocations may not be indicative of the actual amounts that would have been recorded had the Company operated as an independent, publicly traded company for the periods presented.

Allocation of Agenus services, net of approximately $227,000 and $306,000 for the three months ended March 31, 2024 and 2023, respectively, is included in “Operating expenses” in the Company’s statement of operations and “Due to related parties,” of $11.8 million as of March 31, 2024, in the Company’s condensed consolidated balance sheet. Agenus has agreed to not require repayment of the related party balance prior to June 30, 2025.

On February 12, 2024, the Company and Agenus entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million. The Purchase Agreement sets forth the terms and conditions, including representations and warranties, for the Company’s issuance and sale of the Note to Agenus.

The Company may draw down on the principal amount of the Note from time to time with Agenus’s consent in any increment, either in the form of advancements or payments made by Agenus on the Company’s behalf. The Note carries an annual rate of interest rate of 2% (the “Interest Rate”) that accrues from the date funds are paid or advanced by Agenus to the Company. Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026. In the event of a qualified financing, the outstanding principal amount of the Note plus accrued and unpaid interest shall, at Agenus’ election, either be paid in full or converted into equity shares equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the equity securities sold in the qualified financing. Upon a change of control, the Company will pay Agenus an amount equal to (i) 1.5 times the principal then outstanding under the Note and (ii) the amount of accrued interest then outstanding immediately prior to the closing of such change of control.

In March 2024, MiNK received $5.0 million from Agenus and the Note was fully drawn. As of March 31, 2024, the Note had a principal balance of $5.0 million and an accrued and unpaid interest balance of $4,444 and an effective interest rate of 17%.

In January 2023, the Company's CEO (“Dr. Buell”), became an employee of Agenus in the role of Chairman of the Executive Counsel. As an employee of Agenus, Dr. Buell is paid $150,000 annually and was granted an option to acquire 37,500 shares of Agenus common stock that vest over a period of four years.

In 2022, the Company entered into a Master Services Agreement with Atlant Clinical Ltd. (“Atlant”), a subsidiary of Agenus, to provide clinical trial support services to the Company, including an eTMF platform, medical monitoring and data manager services. The Company’s Audit and Finance Committee approved the engagement under its related-party transactions policy for up to $250,000 in services. These services are expected to be completed in 2024. As of March 31, 2024, the Company had entered into work orders with Atlant totaling approximately $167,000, plus out of pocket expenses which are to pass through to Company at cost. For the three months ended March 31, 2024 and 2023, approximately $13,000 and $22,000, respectively, related to these services is included in “Research and development” expense in the Company’s condensed consolidated statements of operations.

Dr. Buell's spouse is a partner in the law firm of Wolf, Greenfield & Sachs, P.C. (“Wolf Greenfield”), which provided legal services to the Company during the periods ended March 31, 2024 and 2023, and continues to do so. For the three months ended March 31, 2024 and 2023, the Company expensed Wolf Greenfield fees totaling approximately $27,000 and $38,000, respectively. Dr. Buell’s spouse does not receive direct compensation from the fees paid to Wolf Greenfield by the Company and the fees paid by the Company to Wolf Greenfield in the period was an insignificant amount of Wolf Greenfield’s revenues. The Company’s Audit and Finance Committee approved these services under its related-party transactions policy.

(8) Fair Value Measurement

The Company measures the Note at fair value. The fair value of the Note at March 31, 2024 was $4.2 million, based on the Level 2 valuation hierarchy of the fair value measurements standard using a scenario based present value methodology that was derived by evaluating the nature and terms of the Note and considering the prevailing economic and market conditions at the balance sheet date. As of March 31, 2024 the Note had a principal balance of $5.0 million. The difference between the determined fair value at the issuance of the Note and the proceeds received was recorded as additional paid-in capital in the Company’s condensed consolidated balance sheets as of March 31, 2024.

(9) Contingencies

The Company may currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or liquidity, litigation is subject to inherent uncertainty and consumes both cash and management attention.

(10) Recent Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on the notes to its consolidated financial statements.

No other new accounting pronouncement issued or effective during the three months ended March 31, 2024 had or is expected to have a material impact on the Company’s consolidated financial statements or disclosures.

(11) Subsequent Events

On May 13, 2024, the Company entered into a Stock Purchase Agreement with a certain investor (the “Purchaser”), pursuant to which the Company issued and sold an aggregate of 4,640,000 shares of Common Stock (the “Common Shares”), at a purchase price of $1.25 per share. The aggregate purchase price paid by the Purchaser for the Common Shares will be approximately $5.8 million, net of offering expenses. The transaction is expected to close on May 14, 2024, subject to customary closing conditions.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

MiNK Therapeutics, Inc. (“we,” “us” and “our”) is a clinical stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf invariant natural killer T (“iNKT”) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (“NK”) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease (“GvHD”). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells.

Our business activities include product research and development, manufacturing, regulatory and clinical development, corporate finance, and support of our collaborations. To be successful, our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. We are a party to an Amended and Restated Intercompany Services Agreement and an Intellectual Property Assignment and License Agreement with Agenus. Under the Amended and Restated Intercompany Services Agreement, Agenus provides us with certain general and administrative support, including, without limitation, financial, facilities management, human resources and information technology administrative support, and we and Agenus provide each other with certain research and development services and other support services, including legal and regulatory support. We are also entitled to use Agenus’ business offices and laboratory space and equipment in exchange for us contributing a proportionate payment for the use of such facilities and equipment, and we will be covered by certain Agenus insurance policies, subject to certain conditions, including us paying the cost of such coverage. Under the Intellectual Property Assignment and License Agreement, Agenus exclusively assigned patent rights and know-how related to our technology to us. We also have a field-limited exclusive license under certain Agenus patents and know-how; and we retain the rights to expand a proprietary pipeline of products and technologies.

Our most advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. iNKTs are a potent class of immune cells and serve as master regulators of immune response, possessing the killing power of NK cells and the memory of T-cells. Our proprietary manufacturing platform allows these cells to be infused in billion-fold numbers, arming the immune system against cancer and other life-threatening diseases. We have established and launched in-house iNKT cell manufacturing and product release capacity to supply more than 5,000 doses per year through a U.S. Food and Drug Administration (“FDA”)-cleared scalable, fully closed, and automatic process. Our Phase 1 clinical trial studying agenT-797 in solid tumor cancers, as a monotherapy and in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab and nivolumab, is currently advancing as a priority program. Encouraging activity was seen with agenT-797 monotherapy and combination, with durable responses and disease stabilization in patients, which was presented at the American Association for Cancer Research (“AACR”) and more recently at the Society of Immunotherapy for Cancer (“SITC”) conference in November 2023.

In our Phase 1 clinical trial, most recently presented at SITC 2023, agenT-797 demonstrated a durable clinical benefit and a tolerable safety profile across various heavily pre-treated solid tumors. This includes non-small cell lung cancer (“NSCLC”), testicular cancer, and gastric cancer. Notably, the median progression-free survival (“PFS”) exceeded six months. Approximately 30% of patients experienced durable disease stabilization, even in cancers that were refractory to all prior therapies, such as pembrolizumab and nivolumab. This was observed in multiple cancer types, including but not limited to NSCLC and testicular cancer. Significantly, a patient with metastatic gastric cancer, who had not responded to anti-PD-1 therapy and standard chemotherapy, achieved a partial response when treated with agenT-797 in combination with nivolumab. This response was ongoing at 10 months. The safety profile of agenT-797 was tolerable, both as a standalone treatment and in combination with PD-1 inhibitors. Treatment doses up to one billion cells showed no neurotoxicity, dose-limiting toxicities, or severe cytokine release syndrome (above grade 3).

Building on these encouraging results, we plan to conduct a randomized phase 1/2 expansion trial. This trial will assess the efficacy of agenT-797 in combination with standard-of-care chemotherapy and immune therapy (pembrolizumab/nivolumab), with or without Agenus’ multifunctional anti-CTLA-4 agent, botensilimab, in relapsed/refractory gastric cancer.

We reported updated data from our Phase 1 clinical trial of agenT-797 in viral acute respiratory distress syndrome (“ARDS”) at the 2023 American Thoracic Society International Conference. We reported an encouraging survival benefit of 75%, compared to ~10-22% in an in-hospital control and time-matched data from the Centers for Disease Control and Prevention. Notably, in addition to a survival benefit, we reported observations that agenT-797 improved lung function and significantly reduced inflammation and secondary infections in the population. There are currently no approved therapies for ARDS and secondary infections are a significant contributor to comorbidity and death in intensive care units; our data contribute favorably as a potential therapeutic and we plan to advance agenT-797 in viral ARDS through strategic collaborations and non-dilutive external financing. Discussions are underway.

In addition, we completed a Phase 1 clinical trial of agenT-797 for the treatment of multiple myeloma and reported at SITC in 2022 that agenT-797 was tolerable to a billion cells/dose and suppressed biomarkers associated with disease progression. This proof of concept Phase 1 underscores the potential application of INKT cells in multiple myeloma and we believe supports the advancement of our armored B cell maturation antigen (“BCMA”)-CAR-INKT program as a potential best in class next generation allogeneic BCMA cell therapy for these patients. Strategic discussions to advance this program are underway.

We are also advancing a pipeline of next-generation allogeneic, engineered iNKT programs. Our two most advanced engineered programs are (1) MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT and (2) MiNK-413, an IL-15 armored CAR-iNKT program targeting BCMA program. MiNK-413 has demonstrated tumor clearance and improved persistence in preclinical models, as well as manufacturing and logistical improvements over current BCMA cell therapies. MiNK-215 has demonstrated efficacy in NSCLC and melanoma preclinical models, promoting curative responses, eliminating tumor burden in the lungs, and enhancing tumor specific CD8+ T cell infiltration through tumor stroma. These data and programs were presented at AACR in 2024, International Cancer Immunotherapy Conference ("CICON") in 2023, SITC in 2023, and the American Society of Cell and Gene Therapy ("ASGCT") in 2023. Investigational new drug (“IND”) enabling activities are underway we expect to submit an IND to the FDA in 2024.

In December 2023, we announced a collaboration with ImmunoScape, Inc. ("ImmunoScape") to discover and develop next-generation T-cell receptor therapies against novel targets in solid tumors. We will combine our unique, proprietary library of T cell antigens with ImmunoScape’s platform for rapid discovery of novel T cell receptors.

Historical Results of Operations

Three Months Ended March 31, 2024 Compared to the Three Months Ended March 31, 2023

Research and development expense

Research and development (“R&D”) expense includes the costs associated with our internal research and development activities, including compensation and benefits, occupancy costs, manufacturing costs, costs of expert consultants, and administrative costs. R&D expense decreased 39% to $2.5 million for the three months ended March 31, 2024 from $4.2 million for the three months ended March 31, 2023. This decrease is primarily due to decreased costs associated with both the timing of our clinical trials and pre-clinical activities as well as decreased personnel costs, primarily due to decreased headcount.

General and administrative expense

General and administrative (“G&A”) expense consists primarily of personnel costs, facility expenses, and professional fees. G&A expense decreased 23% to $1.3 million for the three months ended March 31, 2024 from $1.7 million for the three months ended March 31, 2023. This decrease is primarily due to decreased share based compensation expense.

Interest income, net

Interest income decreased $151,000 for the three months ended March 31, 2024, from income of approximately $168,000 for the three months ended March 31, 2023 to income of approximately $17,000 for the three months ended March 31, 2024, primarily due to decreased interest earned on our money market funds.

Research and Development Programs

R&D program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions.


	For the three months ended March 31,		For the years ended December 31,
	2024		2023		2022
Payroll and personnel costs	$	1,514,854	$	6,814,210	$	5,729,235
Professional fees		403,070		5,283,439		11,607,709
Allocated services		97,106		500,280		1,284,920
Materials and other		534,452		2,892,068		4,493,259
Total	$	2,549,482	$	15,489,997	$	23,115,123

Our product candidates are in various stages of development and significant additional expenditures will be required if we start new clinical trials, encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations and/or bring our product candidates to market. The total cost of any particular clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, number of patients and trial sponsorship. The process of obtaining and maintaining regulatory approvals for new products is lengthy, expensive and uncertain. Because of the current stage of our product candidates, among other factors, we are unable to reliably estimate the cost of completing our research and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence.

Liquidity and Capital Resources

We have incurred annual operating losses since inception in 2017, and we had an accumulated deficit of $137.2 million as of March 31, 2024. We expect to incur losses over the next several years as we continue development of our technologies and product candidates, manage our regulatory processes, initiate and continue clinical trials, and prepare for potential commercialization of products.

In October 2021, we completed an initial public offering of 3,333,334 shares of our common stock, at a public offering price of $12.00 per share. The gross proceeds from the offering, before deducting underwriting discounts, commissions and other offering expenses, were approximately $46.0 million, which includes the exercise of the underwriters option to acquire an additional 500,000 shares at the public offering price, which shares were delivered in November 2021. Underwriting discounts, commissions and other offering expenses, were approximately $6.2 million, resulting in net proceeds of approximately $39.8 million.

In December 2018, we entered into an agreement with the Walloon Region in which the Walloon Region agreed to provide a grant of up to €1.3 million and an advance of up to €8.3 million for the development of one of our research programs. As of March 31, 2024, we had received $881,000 of the grant portion and $5.2 million of the advance. During 2020, we discontinued research efforts related to this program, and in 2021 we provided additional information as requested by the Walloon Region to terminate the agreement. We recognized the grant portion received as income during the years ended December 31, 2019 and 2020. We learned in the second quarter of 2022 that the Walloon Region had obtained a default judgment in the amount of €2,086,712 for repayment of the advance. In view of the default judgment, we reduced the recorded liability and recorded a gain of approximately $2.7 million in our consolidated statement of operations for the year ended December 31, 2022. We have included the remaining balance of $2.3 million in other current liabilities in our condensed consolidated balance sheet at March 31, 2024.

We had a related party note (the "Note") outstanding as of March 31, 2024 of $5.0 million in principal plus accrued and unpaid interest of approximately $4,000. The Note provides that we will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026. In the event of a qualified financing event, as described in the Note, at Agenus’ election, we must pay the principal amount outstanding and any unpaid interest, either in full or in the form of equity securities.

Our cash and cash equivalents balance as of March 31, 2024 was $5.8 million. We believe that our cash and cash equivalents balance, along with additional funding of $5.8 million received after quarter end (see Note 11), will be sufficient to satisfy our liquidity requirements for more than one year from when these financial statements were issued. Because we are dependent on our parent, Agenus, for certain services and deferral of related payments as discussed in Note 7, and Agenus has recently disclosed the existence of a substantial doubt about its ability to continue as a going concern, in accordance with the relevant accounting guidance, we are also required to disclose that substantial doubt exists about our ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q. To support our liquidity requirements beyond one year from when these financial statements are issued we will require additional funding. The financial statements have been prepared on a basis that assumes we will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Management continually monitors our liquidity position and adjusts spending as needed in order to preserve liquidity. Potential sources of additional funding include: (1) seeking strategic partnerships and collaborations, as well as out-licensing opportunities, for our portfolio programs and product candidates, (2) exploring avenues for securing non-dilutive financing, such as grants and collaborations to strengthen our balance sheet, and (3) potential of equity or debt financing options. If additional funding is not obtained through these sources, Agenus has indicated a willingness to loan us additional funds to finance our operations.

Net cash used in operating activities for the three months ended March 31, 2024 and 2023 was $2.5 million and $4.4 million, respectively. Our future ability to generate cash from operations will depend on achieving regulatory approval and market acceptance of our product candidates, and our ability to enter into collaborations.

Forward-Looking Statements

This Quarterly Report on Form 10-Q and other written and oral statements we make from time to time contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). You can identify these forward-looking statements by the fact they use words such as “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will,” “potential,” “opportunity,” and “future,” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. You can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements relate to, among other things, our business strategy, our research and development, our product development efforts, our ability to develop, including our ability to develop and obtain licensure of agenT-797, MiNK-215, and MiNK-413, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, our cash runway and anticipated sources of funds as well as our plans, objectives, expectations, and intentions.

More detailed descriptions of these risks and uncertainties and other risks and uncertainties applicable to our business that we believe could cause actual results to differ materially from any forward-looking statements are included in in Part I-Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. We encourage you to read those descriptions carefully. Although we believe we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved. We caution investors not to place significant reliance on forward-looking statements contained in this document; such statements need to be evaluated in light of all the information contained

in this document. Furthermore, the statements speak only as of the date of this document, and we undertake no obligation to update or revise these statements.

JOBS Act

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to hold non-binding advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.

We may take advantage of these exemptions until the last day of the fiscal year following the fifth anniversary of our initial public offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.235 billion in annual revenue, we have more than $700.0 million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form 10-K) or we issue more than $1.0 billion of non-convertible debt securities over a three-year period. For so long as we remain an emerging growth company, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available exemptions.

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

This item is not required for smaller reporting companies.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our Principal Executive Officer and our Principal Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective and were designed to ensure that information we are required to disclose in the reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure, and is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. It should be noted that any system of controls is designed to provide reasonable, but not absolute, assurances that the system will achieve its stated goals under all reasonably foreseeable circumstances. Our Principal Executive Officer and Principal Financial Officer have each concluded that our disclosure controls and procedures as of the end of the period covered by this report are effective at a level that provides such reasonable assurances.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

We are not a party to any material legal proceedings.

Item 1A. Risk Factors.

Our results of operations and financial condition are subject to numerous risks and uncertainties described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. There have been no material changes to the risk factors described in Part I, Item 1A "Risk Factors" of our 2023 Form 10-K.

Item 5. Other Information.

Trading Plans of Our Directors and Officers

During the quarter ended March 31, 2024, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.

Item 6. Exhibits.


Exhibit Number		Description

4.1		Form of Convertible Promissory Note by and between the Registrant and Agenus Inc., dated February 12, 2024 (Incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 (File No. 001-40908) filed on March 21, 2024).
10.1		Convertible Promissory Note Purchase Agreement by and between the Registrant and Agenus Inc., dated February 12, 2024 (Incorporated by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 (File No. 001-40908) filed on March 21, 2024).
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	MiNK Therapeutics, Inc.

Date: May 14, 2024	By:	/s/ Jennifer S. Buell, Ph.D.
		Jennifer S. Buell, Ph.D.
		President and Chief Executive Officer (Principal Executive Officer)

Date: May 14, 2024	By:	/s/ Christine M. Klaskin
		Christine M. Klaskin
		Treasurer (Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 inkt-ex31_1.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended

I, Jennifer S. Buell, certify that:

I have reviewed this Quarterly Report on Form 10-Q of MiNK Therapeutics, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles;

evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent function):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Date: May 14, 2024			/s/ Jennifer S. Buell, Ph.D.
			Jennifer S. Buell, Ph.D.
			President, Chief Executive Officer and Principal Executive Officer

EX-31.2 3 inkt-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended

I, Christine M. Klaskin, certify that:

I have reviewed this Quarterly Report on Form 10-Q of MiNK Therapeutics, Inc.;

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Date: May 14, 2024			/s/ Christine M. Klaskin
			Christine M. Klaskin
			Treasurer and Principal Financial Officer

EX-32.1 4 inkt-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

Certification

Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of MiNK Therapeutics, Inc. (the “Company”) for the quarterly period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned to his/her knowledge hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(i)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(ii)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


	/s/ Jennifer S. Buell, Ph.D.
	Jennifer S. Buell, Ph.D.
	President, Chief Executive Officer and Principal Executive Officer

	/s/ Christine M. Klaskin
	Christine M. Klaskin
	Treasurer and Principal Financial Officer

Date: May 14, 2024

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Report and should not be considered filed as part of the Report.

EX-101.SCH 5 inkt-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Business and Liquidity link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Accrued and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Share-based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Accrued and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Share-based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Business and Liquidity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Cash and Cash Equivalents - Summary of Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Accrued and Other Current Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Share-based Compensation Plans - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Share-based Compensation Plans - Summary of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Fair Value Measurement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Convertible debt outstanding amount Outstanding principal amount of Note Convertible Debt Convertible Debt, Total Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Document Transition Report Document Transition Report Outstanding at March 31, 2024, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Institutional Money Market Funds Money Market Funds [Member] Stock option, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Dr. Buell. Dr. Buell [Member] Dr. Buell Due to related parties Other long-term liabilities Other Liabilities, Noncurrent Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total Other operating assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Fair Value Measurement Fair Value Disclosures [Text Block] 2021 Employee Stock Purchase Plan. Two Thousand Twenty One Employee Stock Purchase Plan [Member] 2021 Employee Stock Purchase Plan Issuance of related party note (Note 8) Issuance of related party note Issuance of related party note. Employee Bonus Employee Bonus [Member] Employee Bonus. Interest income, net Interest Income (Expense), Net, Total Interest Income (Expense), Net Summary of Share-based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Subsequent Events Subsequent Events [Text Block] Other Liabilities Current [Table] Other Liabilities Current [Table] Other liabilities, current. Related Party Transactions [Abstract] Total current assets Assets, Current Liabilities and Equity Total liabilities and stockholders' deficit Entity Address, State or Province Entity Address, State or Province Options, Outstanding at Beginning Balance Options, Outstanding at Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Weighted average grant-date fair values of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Atlant Clinical Ltd [Member] Atlant Clinical Ltd [Member] Atlant Clinical Ltd. Trading Symbol Trading Symbol Forgiveness of related party liability member. Forgiveness of Related Party Liability [Member] Forgiveness of Related Party Liability Common stock, shares issued Common Stock, Shares, Issued Salary and Wage, Officer, Excluding Cost of Good and Service Sold Compensation paid Schedule of Long-Term Debt Instruments [Table] Beginning Balance, Shares Ending Balance, Shares Shares, Outstanding Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Other Comprehensive Income (Loss), Net of Tax, Total Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Entity Address, City or Town Entity Address, City or Town Related Party Transaction [Line Items] Related Party Transaction [Line Items] Business and Liquidity Business And Liquidity [Text Block] Business and liquidity. Stock issued during period shares stock options exercised and employee stock purchase plan. Stock Issued During Period Shares Stock Options Exercised And Employee Stock Purchase Plan Exercise of stock options and employee share purchases, Shares Options, Expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Subsequent Event Subsequent Event [Member] Subsequent Event Type [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Convertible debt issued, principal amount Debt Instrument, Issued, Principal Issuance of related party note (Note 8) Adjustment to additional paid-in capital issuance of related party note Adjustment to additional paid-in capital issuance of related party note. Cash and Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Vested or expected to vest at March 31, 2024, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Revenue recognized Revenue from Contract with Customer, Including Assessed Tax Equipment, net of accumulated depreciation of $545,095 and $495,638 at March 31, 2024 and December 31, 2023, respectively Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net Vested or expected to vest at March 31, 2024, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Entity Central Index Key Entity Central Index Key Plan Name [Domain] Related Party Related Party [Member] Issuance of stock options for payment of certain employee bonuses Issuance Of Stock Options For Payment Of Certain Employee Bonuses Issuance of stock options for payment of certain employee bonuses. Total current liabilities Liabilities, Current Entity Tax Identification Number Entity Tax Identification Number Legal Fees Legal services fee Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Cash and Cash Equivalents [Abstract] Plan Name [Axis] Total assets Assets Unrecognized share-based compensation expense related to stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Entity Registrant Name Entity Registrant Name Related Party Related Party, Type [Domain] Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Accumulated Deficit Retained Earnings [Member] Nonvested Shares, Outstanding at Beginning Balance Nonvested Shares, Outstanding at Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Stock Issued During Period, Shares, Employee Stock Purchase Plans Number of shares issued Purchases of plant and equipment in accounts payable and accrued liabilities Purchases Of Plant And Equipment In Accounts Payable And Accrued Liabilities Purchases of plant and equipment in accounts payable and accrued liabilities. Minimum Minimum [Member] Significant Accounting Policies Significant Accounting Policies [Text Block] Equity Component Equity Component [Domain] Stock Options Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Debt Disclosure [Abstract] Entity Current Reporting Status Entity Current Reporting Status Common stock, shares authorized Common Stock, Shares Authorized Research and Development Expense, Total Research and development Research and Development Expense Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Clinical research services Clinical Research Services Clinical research services. Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] ASSETS Assets [Abstract] Aggregate purchase price, net of offering expenses Additional funding Proceeds from Issuance of Common Stock Service agreement notice period Service Agreement Notice Period Service agreement notice period. Common stock, par value $0.00001 per share; 150,000,000 shares authorized; 34,699,056 and 34,599,119 shares issued at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Grant and recognition of stock options Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition Adjustments to additional paid in capital share based compensation stock options grant and recognition. Accrued and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Other Liability, Noncurrent, Related and Nonrelated Party Status [Extensible Enumeration] Total Accrued liabilities Accrued Liabilities, Current Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense, Total Share-based compensation Share-Based Payment Arrangement, Noncash Expense Operating loss Operating Income (Loss) Entity Ex Transition Period Entity Ex Transition Period Research and Development Research and Development Expense [Member] Stock Purchase Agreement Stock Purchase Agreement [Member] Stock Purchase Agreement. Total share-based compensation expense Share-Based Payment Arrangement, Expense Impact of change in fair value Impact Of Change In Fair Value Disclosure Impact of change in fair value disclosure. Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Retirement of treasury shares, share Treasury Stock, Shares, Retired Stock Issued During Period, Shares, Restricted Stock Award, Gross Vesting of nonvested shares, Shares Shares issued, vesting of non-vested stock Outstanding at March 31, 2024, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding principal amount of Note Principal balance of note Debt Instrument, Face Amount Other income, net Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Purchase price per share Sale of Stock, Price Per Share Operating expenses: Operating Expenses [Abstract] Subsequent Events [Abstract] Convertible Promissory Note Convertible Promissory Note [Member] Convertible promissory note. Options, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of shares options, granted Other Other Accrued Liabilities, Current Depreciation, Total Depreciation Depreciation Payroll Accrued Salaries, Current Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Convertible debt, interest rate terms Debt Instrument, Interest Rate Terms Business and Liquidity Disclosure [Line Items] Business and Liquidity Disclosure. Equity, Attributable to Parent [Abstract] STOCKHOLDERS' DEFICIT Accrued and unpaid interest balance Accrued and Unpaid Interest Balance Accrued and unpaid interest balance. Stock issued during period value stock options exercised and employee stock purchase plan. Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan Exercise of stock options and employee share purchases Increasing amount of borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Per common share data: Earnings Per Share [Abstract] Other Liabilities, Current [Abstract] Accounting Policies [Abstract] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Earnings Per Share, Basic, Total Basic net loss per common share Earnings Per Share, Basic Cash Equivalents, at Carrying Value, Total Cost Cash Equivalents, at Carrying Value Schedule Of Cash And Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Commitments and contingencies Commitments and Contingencies Income Statement [Abstract] Related Party Related Party, Type [Axis] Due to related parties Due To Related Party Due to related party. Prepaid expenses Increase (Decrease) in Prepaid Expense Options, Vested or expected to vest at March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Statistical Measurement Statistical Measurement [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Document Period End Date Document Period End Date Statistical Measurement Statistical Measurement [Axis] New Intercompany Service Agreement New Intercompany Service Agreement [Member] New Intercompany Service Agreement. Related party note Related party note Related party note. Diluted net loss per common share Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Issuance of shares for employee bonuses Stock Issued During Period, Value, Employee Benefit Plan Debt Instrument, Name [Domain] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Options, Exercisable at March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Related Party Transaction Related Party Transaction [Domain] Purchase Agreement Purchase Agreement [Member] Purchase agreement. Additional paid-in capital Additional Paid in Capital, Common Stock Business And Liquidity [Abstract] Business and liquidity. Non-Vested Shares Non Vested Shares [Member] Non-vested shares. Percentage value of common stock sold in initial public offering Percentage Value Of Common Stock Sold In Initial Public Offering Percentage value of common stock sold in initial public offering. Options, Exercised Option exercises, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Stock option exercises Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Forfeiture of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Purchase Commitment, Excluding Long-Term Commitment [Domain] Contract manufacturing costs Accrued Contract Manufacturing Expense Current Accrued contract manufacturing expense current. Issuance of shares for employee bonuses, shares Stock Issued During Period, Shares, Employee Benefit Plan Shares issued, payment for employee bonuses Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Interactive Data Current Entity Interactive Data Current Issuance of common stock, $0.00001 par value, for payment of certain employee bonuses Stock Issued Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Nonvested Shares, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Exercised, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Business And Liquidity Disclosure [Table] Business And Liquidity Disclosure. Equity Components Equity Components [Axis] Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Vested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Local Phone Number Local Phone Number Sale of Stock [Axis] Exercisable at March 31, 2024, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accrued liabilities and other current liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Statement of Cash Flows [Abstract] Share retirement, Shares Stock Repurchased and Retired During Period, Shares Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Common stock, par value Common Stock, Par or Stated Value Per Share Qualified financing terms Qualified Financing Terms Qualified financing terms. Weighted average period of unrecognized share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Related party transaction, description Related Party Transaction, Description of Transaction Vested or expected to vest at March 31, 2024, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Stock issued during period, shares, employee benefit plan net of shares withheld for taxes. Stock Issued During Period, Shares, Employee Benefit Plan Net of Shares Withheld for Taxes Shares issued, payment for employee bonuses, net of shares withheld for taxes Maximum Maximum [Member] Interest accrued on related party note Interest accrued on related party note Interest accrued on related party note. Research Services Research Services [Member] Research Services. Related Party Transaction Related Party Transaction [Axis] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Percentage of per share price of equity securities sold in qualified financing Percentage of Per Share Price of Equity Securities Sold in Qualified Financing Percentage of per share price of equity securities sold in qualified financing. General and Administrative General and Administrative Expense [Member] Options, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Forfeiture of restricted stock, shares Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Issuance of shares for employee bonus, treasury shares Treasury Stock Issued During Period Shares Employee Benefit Plan Treasury stock issued during period shares employee benefit plan. Schedule of Anti-dilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] City Area Code City Area Code Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Sale of stock, transaction date Sale of Stock, Transaction Date Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Equipment, net of accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment General and Administrative Expense, Total General and administrative General and Administrative Expense Weighted Average Number of Shares Outstanding, Basic, Total Weighted average number of common shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Employee Stock [Member] 2021 Employee Stock Purchase Plan Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Business Services and Occupancy Costs Business Services And Occupancy Costs [Member] Business Services and Occupancy Costs. Purchase of treasury shares to satisfy tax withholdings Purchase Of Treasury Shares To Satisfy Tax Withholdings Purchase of treasury shares to satisfy tax withholdings. Statement [Table] Statement [Table] Summary of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Period of license agreement Period Of License Agreement Period of license agreement. Document Fiscal Period Focus Document Fiscal Period Focus Operating Expenses Operating Income (Loss) [Member] Related Party Transactions Related Party Transactions Disclosure [Text Block] Professional fees Accrued Professional Fees, Current Statement [Line Items] Statement [Line Items] Total anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Event [Line Items] Common Stock Common Stock [Member] Debt Instrument [Line Items] Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other current assets Other Assets, Current Exercisable at March 31, 2024, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Prepaid Expense, Current, Total Prepaid expenses Prepaid Expense, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Option Fair Value of Financial Instruments, Policy [Policy Text Block] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Percentage of service cost Percentage Of Service Cost Percentage of service cost. Cover [Abstract] Long-Term Purchase Commitment, Category of Item Purchased Long-Term Purchase Commitment, Category of Item Purchased [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Fair value of note Notes Payable, Fair Value Disclosure Sale of Stock [Domain] Agenus Inc Agenus Inc [Member] Agenus Inc. Granted, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Wolf, Greenfield & Sachs, P.C. Wolf, Greenfield & Sachs, P.C. [Member] Wolf, Greenfield & Sachs, P.C. Security Exchange Name Security Exchange Name Summary of Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Expenses from transactions with related party Operating Costs and Expenses Operating Costs and Expenses, Total Other Liabilities Current [Line Items] Other Liabilities Current [Line Items] Other liabilities, current. Forfeited, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Option exercises Stock Issued During Period, Value, Stock Options Exercised Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Vesting of nonvested shares Stock Issued During Period, Value, Restricted Stock Award, Gross Summary of Accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Period for breach of payment obligations Period For Breach Of Payment Obligations Period for breach of payment obligations. Category of Item Purchased Category of Item Purchased [Axis] Entity File Number Securities Act File Number Contingencies Contingencies Disclosure [Text Block] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Payment Arrangement [Abstract] Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Debt Instrument [Axis] Outstanding at Beginning Balance, Weighted Average Grant Date Fair Value Outstanding at Ending Balance, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Terminate license agreement period Terminate License Agreement Period Terminate license agreement period. Entity Address, Address Line Two Entity Address, Address Line Two Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Summary of Non-vested Stock Activity Schedule of Nonvested Share Activity [Table Text Block] Aggregate number of shares issued and sold Sale of Stock, Number of Shares Issued in Transaction Research services Accrued Research Services Current Accrued research services current. Unrecognized share-based compensation expense related to non-vested shares Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Shares issued, withheld to cover taxes Net Loss Per Share Earnings Per Share [Text Block] Entity Address, Address Line One Entity Address, Address Line One Estimated Fair Value Cash and Cash Equivalents, Fair Value Disclosure Antidilutive Securities Antidilutive Securities [Axis] Other current liabilities Other current liabilities Other Liabilities, Current Convertible debt, annual interest rate Debt Instrument, Interest Rate During Period Research and Development Agreement Research and Development Arrangement [Member] Subsequent Event Type [Domain] Income Statement Location Income Statement Location [Axis] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Percentage of computation of interest Percentage Of Computation Of Interest Percentage of computation of interest. Recognition of parent stock options APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Title of 12(b) Security Title of 12(b) Security Individual Services Individual Services [Member] Individual Services. Other income, net: Other Nonoperating Income (Expense) [Abstract] Treasury Stock Treasury Stock, Common [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Subsequent Event [Table] Stock option grants, term Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Repayable advance received Repayable Advance Received Repayable advance received. Exercisable at March 31, 2024, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Loss Contingency [Abstract] Share-based Compensation Plans Share-Based Payment Arrangement [Text Block] Forfeited, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Income Statement Location Income Statement Location [Domain] Granted, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Document Type Document Type Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Document Quarterly Report Document Quarterly Report Purchase Commitment, Excluding Long-Term Commitment [Axis] Other Income (Expense), Net Other Income Expense Net [Member] Other Income (Expense), Net. Nonvested Shares, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Convertible Affiliated Note Convertible Affiliated Note [Member] convertible affiliated note. Entity Filer Category Entity Filer Category Supplemental disclosures - non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Expired, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Foreign currency translation gain (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Accrued Liabilities, Current [Abstract] Proceeds from issuance of related party note Proceeds from issuance of related party note Proceeds from issuance of related party note. Beginning Balance Ending Balance Equity, Attributable to Parent Total stockholders' deficit Intercompany allocation included in expense Intercompany Allocation Included in Expense Intercompany allocation included in expense. Net loss Net loss Proceeds from employee stock purchases and option exercises. Proceeds From Employee Stock Purchases And Option Exercises Proceeds from employee stock purchases and option exercises Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Statement of Financial Position [Abstract] Weighted average number of common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Outstanding at Beginning Balance, Weighted Average Exercise Price Outstanding at Ending Balance, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Compensation paid Salary and Wage, Excluding Cost of Good and Service Sold Salary and Wage, Excluding Cost of Good and Service Sold, Total Work order received from related party Work Order Received From Related Party Work order received from related party. Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Fair Value Disclosures [Abstract] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Payments to Acquire Property, Plant, and Equipment, Total Purchases of plant and equipment Payments to Acquire Property, Plant, and Equipment Nonvested Shares, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Initial public offering, net of offering costs, shares Stock Issued During Period, Shares, New Issues Accounting Standards Update and Change in Accounting Principle [Abstract] XML 7 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2024	May 10, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Entity Registrant Name	MiNK Therapeutics, Inc.
Entity Central Index Key	0001840229
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-40908
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		34,727,639
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Common Stock, par value $0.00001 per share
Trading Symbol	INKT
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2142067
Entity Address, Address Line One	149 Fifth Avenue
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10010
City Area Code	212
Local Phone Number	994-8250
Document Quarterly Report	true
Document Transition Report	false

XML 8 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 5,817,080	$ 3,367,229
Prepaid expenses	59,394	53,111
Other current assets	122,477	177,964
Total current assets	5,998,951	3,598,304
Equipment, net of accumulated depreciation of $545,095 and $495,638 at March 31, 2024 and December 31, 2023, respectively	894,992	953,977
Total assets	6,893,943	4,552,281
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	3,486,999	3,911,973
Accrued liabilities	5,282,707	5,037,361
Other current liabilities	2,338,554	2,453,251
Total current liabilities	11,108,260	11,402,585
Related party note	4,211,566
Other long-term liabilities	31,600	48,072
Due to related parties	11,841,724	11,157,073
Commitments and contingencies
STOCKHOLDERS' DEFICIT
Common stock, par value $0.00001 per share; 150,000,000 shares authorized; 34,699,056 and 34,599,119 shares issued at March 31, 2024 and December 31, 2023, respectively	347	346
Additional paid-in capital	117,296,454	115,772,085
Accumulated other comprehensive loss	(385,780)	(430,947)
Accumulated deficit	(137,210,228)	(133,396,933)
Total stockholders' deficit	(20,299,207)	(18,055,449)
Total liabilities and stockholders' deficit	$ 6,893,943	$ 4,552,281

XML 9 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Equipment, net of accumulated depreciation	$ 545,095	$ 495,638
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	34,699,056	34,599,119

XML 10 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 2,549,482	$ 4,193,562
General and administrative	1,280,432	1,660,534
Operating loss	(3,829,914)	(5,854,096)
Other income, net:
Interest income, net	16,619	168,055
Net loss	$ (3,813,295)	$ (5,686,041)
Per common share data:
Basic net loss per common share	$ (0.11)	$ (0.17)
Diluted net loss per common share	$ (0.11)	$ (0.17)
Weighted average number of common shares outstanding, basic	34,642,915	33,966,921
Weighted average number of common shares outstanding, diluted	34,642,915	33,966,921
Other comprehensive income (loss):
Foreign currency translation gain (loss)	$ 45,167	$ (81,335)
Comprehensive loss	$ (3,768,128)	$ (5,767,376)

XML 11 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2022	$ (401,303)	$ 339	$ 110,829,900		$ (292,468)	$ (110,939,074)
Beginning Balance, Shares at Dec. 31, 2022		33,856,428
Net loss	(5,686,041)					(5,686,041)
Other comprehensive income (loss)	(81,335)				(81,335)
Exercise of stock options and employee share purchases, Shares		99,555
Exercise of stock options and employee share purchases	45,496	$ 1	45,495
Vesting of nonvested shares, Shares		30,413
Grant and recognition of stock options	887,811		887,811
Recognition of parent stock options	33,328		33,328
Issuance of shares for employee bonuses	346,344	$ 5	726,260	$ (379,921)
Issuance of shares for employee bonuses, shares		476,804
Issuance of shares for employee bonus, treasury shares				(163,759)
Retirement of treasury shares	379,919	$ (2)		$ 379,921
Retirement of treasury shares, share		(163,759)		163,759
Ending Balance at Mar. 31, 2023	(4,475,781)	$ 343	112,522,794		(373,803)	(116,625,115)
Ending Balance, Shares at Mar. 31, 2023		34,299,441
Beginning Balance at Dec. 31, 2023	(18,055,449)	$ 346	115,772,085		(430,947)	(133,396,933)
Beginning Balance, Shares at Dec. 31, 2023		34,599,119
Net loss	(3,813,295)					(3,813,295)
Other comprehensive income (loss)	45,167				45,167
Issuance of related party note (Note 8)	792,878		792,878
Exercise of stock options and employee share purchases, Shares		22,851
Exercise of stock options and employee share purchases	$ 6,896		6,896
Option exercises, Shares	15,469
Vesting of nonvested shares		$ 1	(1)
Vesting of nonvested shares, Shares	77,086	77,086
Grant and recognition of stock options	$ 697,563		697,563
Recognition of parent stock options	27,033		27,033
Ending Balance at Mar. 31, 2024	$ (20,299,207)	$ 347	$ 117,296,454		$ (385,780)	$ (137,210,228)
Ending Balance, Shares at Mar. 31, 2024		34,699,056

XML 12 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (3,813,295)	$ (5,686,041)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	53,831	45,686
Share-based compensation	592,006	921,139
Interest accrued on related party note	4,444
Changes in operating assets and liabilities:
Prepaid expenses	(6,349)	(10,010)
Accounts payable	(424,439)	153,919
Accrued liabilities and other current liabilities	324,451	(549,527)
Other operating assets and liabilities	727,144	758,424
Net cash used in operating activities	(2,542,207)	(4,366,410)
Cash flows from investing activities:
Purchases of plant and equipment		(13,500)
Net cash used in investing activities		(13,500)
Cash flows from financing activities:
Proceeds from issuance of related party note	5,000,000
Proceeds from employee stock purchases and option exercises	6,896	45,496
Purchase of treasury shares to satisfy tax withholdings		(379,921)
Net cash provided by (used in) financing activities	5,006,896	(334,425)
Effect of exchange rate changes on cash	(14,838)	(29,340)
Net increase (decrease) in cash and cash equivalents	2,449,851	(4,743,675)
Cash and cash equivalents, beginning of period	3,367,229	19,635,725
Cash and cash equivalents, end of period	5,817,080	14,892,050
Supplemental cash flow information:
Cash paid for interest	5,116	9,961
Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities		23,042
Issuance of stock options for payment of certain employee bonuses	132,590
Issuance of related party note (Note 8)	$ 792,878
Issuance of common stock, $0.00001 par value, for payment of certain employee bonuses		$ 726,263

XML 13 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	Mar. 31, 2024 $ / shares
Common stock, par value	$ 0.00001
Employee Bonus
Common stock, par value	$ 0.00001

XML 14 R8.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($)	3 Months Ended
Pay vs Performance Disclosure - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (3,813,295)	$ (5,686,041)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

XML 15 R9.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 16 R10.htm IDEA: XBRL DOCUMENT

Business and Liquidity

3 Months Ended

Mar. 31, 2024

Business And Liquidity [Abstract]

Business and Liquidity

(1) Business and Liquidity

XML 17 R11.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Significant Accounting Policies

(2) Significant Accounting Policies

Fair Value Option

Other Policies

Financial Statement Preparation

XML 18 R12.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Net Loss Per Share

(3) Net Loss Per Share


	Three Months Ended March 31,
	2024		2023
Stock options		8,246,769		6,720,366
Non-vested shares		781,893		885,756

XML 19 R13.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents

3 Months Ended

Mar. 31, 2024

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents

(4) Cash and Cash Equivalents

Cash equivalents consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024				December 31, 2023
	Cost		Estimated Fair Value		Cost		Estimated Fair Value
Institutional money market funds	$	5,424	$	5,424	$	2,899	$	2,899

XML 20 R14.htm IDEA: XBRL DOCUMENT

Accrued and Other Current Liabilities

3 Months Ended

Mar. 31, 2024

Accrued Liabilities, Current [Abstract]

Accrued and Other Current Liabilities

(5) Accrued and Other Current Liabilities

Accrued liabilities consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024		December 31, 2023
Payroll	$	2,067	$	1,831
Professional fees		492		398
Research services		294		302
Contract manufacturing costs		2,430		2,430
Other		—		76
Total	$	5,283	$	5,037

XML 21 R15.htm IDEA: XBRL DOCUMENT

Share-based Compensation Plans

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Share-based Compensation Plans

(6) Share-based Compensation Plans

A summary of option activity for the three-month period ended March 31, 2024 is presented below:


	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at December 31, 2023		6,945,716		$	2.03
Granted		1,346,997			0.87
Exercised		(15,469	)		0.01
Forfeited		(30,262	)		1.72
Expired		(213	)		2.28
Outstanding at March 31, 2024		8,246,769		$	1.85		7.51	$	1,926,229
Vested or expected to vest at March 31, 2024		8,246,769		$	1.85		7.51	$	1,926,229
Exercisable at March 31, 2024		4,534,989		$	1.58		6.55	$	1,875,043

A summary of non-vested stock activity for the three-month period ended March 31, 2024 is presented below:


	Nonvested Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2023		789,503		$	1.18
Granted		69,476			0.95
Vested		(77,086	)		1.04
Forfeited		—			—
Outstanding at March 31, 2024		781,893		$	1.17

As of March 31, 2024, there was $0.8 million of unrecognized share-based compensation expense related to these non-vested shares which will be recognized over a weighted average period of 4.4 years.


	Three Months Ended March 31,
	2024		2023
Research and development	$	122	$	141
General and administrative		603		780
Total share-based compensation expense	$	725	$	921

XML 22 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2024

Related Party Transactions

(7) Related Party Transactions

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 23 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurement

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurement

(8) Fair Value Measurement

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 24 R18.htm IDEA: XBRL DOCUMENT

Contingencies

3 Months Ended

Mar. 31, 2024

Loss Contingency [Abstract]

Contingencies

(9) Contingencies

- Definition

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

+ References + Details

XML 25 R19.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Mar. 31, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recent Accounting Pronouncements	(10) Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on the notes to its consolidated financial statements. No other new accounting pronouncement issued or effective during the three months ended March 31, 2024 had or is expected to have a material impact on the Company’s consolidated financial statements or disclosures.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

+ Details

XML 26 R20.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

Subsequent Events

(11) Subsequent Events

XML 27 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Fair Value Option	Fair Value Option Under the Fair Value Option subsection of ASC Subtopic 825-10, Financial Instruments – Overall, the Company has the irrevocable option to report most financial assets and liabilities at fair value on an instrument-by-instrument basis with changes in fair value reported in earnings. The Company has elected to report the related party note it issued to Agenus on February 12, 2024 (the “Note”) at fair value. The fair value of the Note is determined on a scenario based present value methodology. The outstanding principal amount of the Note was $5.0 million at March 31, 2024.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on the notes to its consolidated financial statements. No other new accounting pronouncement issued or effective during the three months ended March 31, 2024 had or is expected to have a material impact on the Company’s consolidated financial statements or disclosures.

XML 28 R22.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of Anti-dilutive Securities

Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of March 31, 2024 and 2023, as they would be anti-dilutive:


	Three Months Ended March 31,
	2024		2023
Stock options		8,246,769		6,720,366
Non-vested shares		781,893		885,756

XML 29 R23.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents (Tables)

3 Months Ended

Mar. 31, 2024

Cash and Cash Equivalents [Abstract]

Summary of Cash Equivalents

Cash equivalents consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024				December 31, 2023
	Cost		Estimated Fair Value		Cost		Estimated Fair Value
Institutional money market funds	$	5,424	$	5,424	$	2,899	$	2,899

XML 30 R24.htm IDEA: XBRL DOCUMENT

Accrued and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2024

Accrued Liabilities, Current [Abstract]

Summary of Accrued liabilities

Accrued liabilities consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024		December 31, 2023
Payroll	$	2,067	$	1,831
Professional fees		492		398
Research services		294		302
Contract manufacturing costs		2,430		2,430
Other		—		76
Total	$	5,283	$	5,037

XML 31 R25.htm IDEA: XBRL DOCUMENT

Share-based Compensation Plans (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Summary of Option Activity

A summary of option activity for the three-month period ended March 31, 2024 is presented below:


	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at December 31, 2023		6,945,716		$	2.03
Granted		1,346,997			0.87
Exercised		(15,469	)		0.01
Forfeited		(30,262	)		1.72
Expired		(213	)		2.28
Outstanding at March 31, 2024		8,246,769		$	1.85		7.51	$	1,926,229
Vested or expected to vest at March 31, 2024		8,246,769		$	1.85		7.51	$	1,926,229
Exercisable at March 31, 2024		4,534,989		$	1.58		6.55	$	1,875,043

Summary of Non-vested Stock Activity

A summary of non-vested stock activity for the three-month period ended March 31, 2024 is presented below:


	Nonvested Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2023		789,503		$	1.18
Granted		69,476			0.95
Vested		(77,086	)		1.04
Forfeited		—			—
Outstanding at March 31, 2024		781,893		$	1.17

Summary of Share-based Compensation Expense

The impact on the Company’s results of operations from share-based compensation for the three months ended March 31, 2024 and 2023, was as follows (in thousands):


	Three Months Ended March 31,
	2024		2023
Research and development	$	122	$	141
General and administrative		603		780
Total share-based compensation expense	$	725	$	921

XML 32 R26.htm IDEA: XBRL DOCUMENT

Business and Liquidity - Additional Information (Details) - USD ($)	May 13, 2024	Mar. 31, 2024	Dec. 31, 2023
Business and Liquidity Disclosure [Line Items]
Accumulated deficit		$ 137,210,228	$ 133,396,933
Cash and cash equivalents		$ 5,817,080	$ 3,367,229
Subsequent Event
Business and Liquidity Disclosure [Line Items]
Additional funding	$ 5,800,000

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

XML 33 R27.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Additional Information (Details) $ in Millions	Mar. 31, 2024 USD ($)
Debt Instrument [Line Items]
Outstanding principal amount of Note	$ 5.0
Convertible Affiliated Note
Debt Instrument [Line Items]
Outstanding principal amount of Note	$ 5.0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 34 R28.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Schedule of Anti-dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total anti-dilutive securities	8,246,769	6,720,366
Non-Vested Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total anti-dilutive securities	781,893	885,756

XML 35 R29.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents - Summary of Cash Equivalents (Details) - Institutional Money Market Funds - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Cash and Cash Equivalents [Line Items]
Cost	$ 5,424	$ 2,899
Estimated Fair Value	$ 5,424	$ 2,899

XML 36 R30.htm IDEA: XBRL DOCUMENT

Accrued and Other Current Liabilities - Summary of Accrued liabilities (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Payroll	$ 2,067,000	$ 1,831,000
Professional fees	492,000	398,000
Research services	294,000	302,000
Contract manufacturing costs	2,430,000	2,430,000
Other		76,000
Total	$ 5,282,707	$ 5,037,361

XML 37 R31.htm IDEA: XBRL DOCUMENT

Accrued and Other Current Liabilities - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2024	Dec. 31, 2023
Other Liabilities Current [Line Items]
Other current liabilities		$ 2,338,554	$ 2,453,251
Research and Development Agreement
Other Liabilities Current [Line Items]
Other current liabilities		$ 2,300,000	$ 2,300,000
Research and Development Agreement \| Other Income (Expense), Net
Other Liabilities Current [Line Items]
Repayable advance received	$ 2,300,000

XML 38 R32.htm IDEA: XBRL DOCUMENT

Share-based Compensation Plans - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant-date fair values of options granted	$ 0.69	$ 1.74
Unrecognized share-based compensation expense related to stock options	$ 3.0
Weighted average period of unrecognized share-based compensation expense	4 years 4 months 24 days
Stock option exercises	15,469
Shares issued, vesting of non-vested stock	77,086
Unrecognized share-based compensation expense related to non-vested shares	$ 0.8
2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued	7,382
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option grants, term	10-year
Weighted average period of unrecognized share-based compensation expense	1 year 9 months 18 days
Minimum \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option, vesting period	3 years
Maximum \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option, vesting period	4 years

XML 39 R33.htm IDEA: XBRL DOCUMENT

Share-based Compensation Plans - Summary of Option Activity (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Options, Outstanding at Beginning Balance \| shares	6,945,716
Options, Granted \| shares	1,346,997
Options, Exercised \| shares	(15,469)
Options, Forfeited \| shares	(30,262)
Options, Expired \| shares	(213)
Options, Outstanding at Ending Balance \| shares	8,246,769
Options, Vested or expected to vest at March 31, 2024 \| shares	8,246,769
Options, Exercisable at March 31, 2024 \| shares	4,534,989
Outstanding at Beginning Balance, Weighted Average Exercise Price \| $ / shares	$ 2.03
Granted, Weighted Average Exercise Price \| $ / shares	0.87
Exercised, Weighted Average Exercise Price \| $ / shares	0.01
Forfeited, Weighted Average Exercise Price \| $ / shares	1.72
Expired, Weighted Average Exercise Price \| $ / shares	2.28
Outstanding at Ending Balance, Weighted Average Exercise Price \| $ / shares	1.85
Vested or expected to vest at March 31, 2024, Weighted Average Exercise Price \| $ / shares	1.85
Exercisable at March 31, 2024, Weighted Average Exercise Price \| $ / shares	$ 1.58
Outstanding at March 31, 2024, Weighted Average Remaining Contractual Term	7 years 6 months 3 days
Vested or expected to vest at March 31, 2024, Weighted Average Remaining Contractual Term	7 years 6 months 3 days
Exercisable at March 31, 2024, Weighted Average Remaining Contractual Term	6 years 6 months 18 days
Outstanding at March 31, 2024, Aggregate Intrinsic Value \| $	$ 1,926,229
Vested or expected to vest at March 31, 2024, Aggregate Intrinsic Value \| $	1,926,229
Exercisable at March 31, 2024, Aggregate Intrinsic Value \| $	$ 1,875,043

XML 40 R34.htm IDEA: XBRL DOCUMENT

Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Nonvested Shares, Outstanding at Beginning Balance \| shares	789,503
Nonvested Shares, Granted \| shares	69,476
Nonvested Shares, Vested \| shares	(77,086)
Nonvested Shares, Outstanding at Ending Balance \| shares	781,893
Outstanding at Beginning Balance, Weighted Average Grant Date Fair Value \| $ / shares	$ 1.18
Granted, Weighted Average Grant Date Fair Value \| $ / shares	0.95
Vested, Weighted Average Grant Date Fair Value \| $ / shares	1.04
Outstanding at Ending Balance, Weighted Average Grant Date Fair Value \| $ / shares	$ 1.17

XML 41 R35.htm IDEA: XBRL DOCUMENT

Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 725	$ 921
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	122	141
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 603	$ 780

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

XML 42 R36.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Details) - USD ($)		1 Months Ended		3 Months Ended		12 Months Ended
	Feb. 12, 2024	Mar. 31, 2024	Jan. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Due to related parties		$ 11,841,724		$ 11,841,724		$ 11,157,073
Principal balance of note		5,000,000		$ 5,000,000
Number of shares options, granted				1,346,997
Stock Options \| Maximum
Related Party Transaction [Line Items]
Stock option, vesting period				4 years
Stock Options \| Minimum
Related Party Transaction [Line Items]
Stock option, vesting period				3 years
Related Party
Related Party Transaction [Line Items]
Due to related parties		$ 11,800,000		$ 11,800,000
Agenus Inc
Related Party Transaction [Line Items]
Period of license agreement				3 years
Period for breach of payment obligations				45 days
Terminate license agreement period				90 days
Related party transaction, description				The Company may terminate the New Assignment and License Agreement without cause upon 90 days’ prior written notice to Agenus. Either party may terminate if there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice.
Intercompany allocation included in expense				$ 227,000	$ 306,000
Percentage of per share price of equity securities sold in qualified financing	80.00%
Qualified financing terms	In the event of a qualified financing, the outstanding principal amount of the Note plus accrued and unpaid interest shall, at Agenus’ election, either be paid in full or converted into equity shares equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the equity securities sold in the qualified financing. Upon a change of control, the Company will pay Agenus an amount equal to (i) 1.5 times the principal then outstanding under the Note and (ii) the amount of accrued interest then outstanding immediately prior to the closing of such change of control.
Agenus Inc \| Purchase Agreement \| Convertible Promissory Note
Related Party Transaction [Line Items]
Convertible debt issued, principal amount	$ 5,000,000
Convertible debt, annual interest rate	2.00%	17.00%
Convertible debt, interest rate terms	Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026.
Convertible debt outstanding amount		$ 5,000,000		5,000,000
Principal balance of note		5,000,000		5,000,000
Accrued and unpaid interest balance		4,444		$ 4,444
Agenus Inc \| New Intercompany Service Agreement
Related Party Transaction [Line Items]
Percentage of service cost				10.00%
Service agreement notice period				60 days
Agenus Inc \| Individual Services
Related Party Transaction [Line Items]
Service agreement notice period				30 days
Agenus Inc \| Business Services and Occupancy Costs
Related Party Transaction [Line Items]
Percentage of service cost				105.00%
Agenus Inc \| Research Services
Related Party Transaction [Line Items]
Percentage of service cost				110.00%
Atlant Clinical Ltd [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party							$ 250,000
Work order received from related party		$ 167,000		$ 167,000
Atlant Clinical Ltd [Member] \| Research and Development
Related Party Transaction [Line Items]
Clinical research services				13,000	22,000
Wolf, Greenfield & Sachs, P.C.
Related Party Transaction [Line Items]
Legal services fee				$ 27,000	$ 38,000
Dr. Buell
Related Party Transaction [Line Items]
Compensation paid						$ 150,000
Dr. Buell \| Stock Options
Related Party Transaction [Line Items]
Number of shares options, granted			37,500

XML 43 R37.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Additional Information (Details) $ in Millions	Mar. 31, 2024 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Principal balance of note	$ 5.0
Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of note	$ 4.2

XML 44 R38.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Details) - Subsequent Event $ / shares in Units, $ in Millions	May 13, 2024 USD ($) $ / shares shares
Subsequent Event [Line Items]
Aggregate purchase price, net of offering expenses	$ 5.8
Stock Purchase Agreement
Subsequent Event [Line Items]
Sale of stock, transaction date	May 13, 2024
Stock Purchase Agreement \| Common Stock
Subsequent Event [Line Items]
Aggregate number of shares issued and sold \| shares	4,640,000
Purchase price per share \| $ / shares	$ 1.25
Aggregate purchase price, net of offering expenses	$ 5.8

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
67+VDM-)WBSX)7J ) M+\I*8?N [^?H"@M&V&(S^;[?:&)TK:"0/[H"UC]FP(Y$MA6P01NPP<'4^,(5 MI@AOO2[9QJU+>LTWL'SFSWF9Q'X_C,*SH;O<5/7:+HQ\+PC#UF[+X;!U.#SH M\!UG)X\@E;[+V=[G?I#B7Z_G2&1;:J-6;?1?Y'-TS( =B6PK8'$;L/C(^1R_ MRM,H[L5GP4XZOS:+XT$TV,UF=Z,&%B 6MC60*.454W7]:%?;[N/"%MV=];'N M2NHFX@]-W=+HZK @3"(*N=-VVPUQW5B",@=Z? M&ULK53O3]LP$/U73AF:0-I(F@0&K(TT6JHA M#0G1P3Y,^V"2:V/AV,%V6OCO=W9"5$1 3-J7Q#_N/;]W]MUXH_2=*1$M/%1" MFDE06EN?A*')2ZR8V55(DPCJ+#L&)2-L:KJP*2@XK+]LXF9CE. JI-@WJ-0?;QP^@P M^CID^C^1/4M!TJ<@>8L]FRICAPRVJ$.//=,6E 8%+@D7[ M7PX"T&T[:2=6U;XB;Y6E^O;#DCHP:A= ^TNE[-/$%7G?T[._4$L#!!0 ( M (P[KECG[B?.SP( &L( 9 >&PO=V]R:W-H965TX9?Q Y@$2/!2W%S,JEW%[9MDAS*+"X8%LHU9N, M\0)+U>4;6VPYX+41%=3V'">T"TQ**YF:9PN>3%DE*2EAP9&HB@+SIQN@;#^S M7.OPX(YLP!'F_77#5LUN7-2F@%(25B$,VLZ[=JWFLXTW =P)[ MT6DCG68X& @JIU Y8W78P!TJUD<+XW7A:[9!:V&T?W#^8W%4N M*RQ@SN@/LI;YS(HMM(8,5U3>L?U':/*9:+^446&N:-_$.A9**R%9T8@504'* M^HX?FSIT!&YP0N U N]O!7XC\$VB-9E)ZQ9+G$PYVR.NHY6;;IC:&+7*AI1Z M%I>2J[=$Z61RG::\@C7"Y1I]E3EP-*\XAU*BSP2O""62@$#OT+*>9<0R=)#0 M3L#9+4A,J'BK0N^7M^CL]=NI+16?'L5.&Y:;FL4[P?(%\PODN^?(<[Q@0#X? ME]]"VLK]8[FMJM*6QFM+XQD__X72= IQWE;GY_5*2*X^PE]#>=;&P;"Q7IA7 M8HM3F%EJY0G@.["2-Z_DPX:0WM'<9] G[8;[CG20,6\)PE'#. M2O,-JPVEK#+5J#@I-RAE0@["AGW8P'?ZM"_''>%&+6XTBFOVIR&N4=F_+K>H M!Q^%)]'C%CT>1?_&)!Y<17%O=4R\V(N9XS)0T<[M]/0, #D. 9 >&PO=V]R:W-H965TVB5(:=BT2.U6M>KV8=H'!R[! M*MC,=I)6VH^?#82&BM!&H_D0;+CG\=UCSMR--HS?BQA HH8JFF?&F*C ..-?=';"430N&: M([%*4\P?+R!AF[%A&]L;-V092WW#]$<97L(MR+OLFJN96;%$) 4J"*.(PV)L M3.SSP+8T(+?X06 C=L9(AS)G[%Y/9M'8L+1'D$ H-056ES5,(4DTD_+C3TEJ M5&MJX.YXR_XE#UX%,\<"IBSY22(9CXVA@2)8X%4B;]CF*Y0!]31?R!*1_Z-- M:6L9*%P)R=(2K#Q("2VN^*$48@=@]_< G!+@/ =X>P!N"7!?"_!*@)WRP'73%J(P%^DPCB.H$I@JHBLK91G7AM#(&$)XBUSY!CN4X M#0Y-V^%7F%=PKP$>O'YUMR4:M]HC-^=S]_ 5^[*[']L]^G6I3-%,0BI^-^E> M\'K-O/I(.1<9#F%LJ#-# %^#X7]X9_>M3TV:=4D6=$16T].K]/3:V$L]PU+# MY$G7)@E;J0Z5L"#KYV3Z1%[[CNL.>SWUDJUWU6FP\WJNT[,KNUK@O2KP7FO@ M-\I#S,,XS_8 UNK4SU*MP63) ?2H28%6SD,5Z)(LZ(BLIF6_TK+_1DG9[U+/ M+LF"CLAJ>@XJ/0?=)64KU:$2#AJ2TM*_9TGYLETM\&$5^/ _DQ+]+3_-,QJR M%-#1YP=5]@DX/D'?H#%E6U<\5)\NR8*.R&I*GU5*G[U1RIYUJ6>79$%'9#4] M;>NI>+1>>'J*K=#(W*FU M4^#+O&<1*&0K*HNRN[I;]463O!LPG\R+IDJ5F4M"!4I@H:#6Z4!]SWC1IQ03 MR;*\&ULQ5E=;^(X M%/TK5G:TFI':)@[AHUU *G1&6VF915-UYV&U#RZY@-7$9FT#9;4_?NPDY(,& M=T"@]J%-C._Q/,U=J<>.Z M@YUMPS #\+\'<"<+ GH)$%-!*B:68)K3NB2+\K^!H)TUNC MF8=$FR1:LZ',3..#$OI3JN-4_V%.!%P:(4(TY+%>'9(D^HXCPB2Z1+=A2$T# MB= ]2Y>-^?CC'2A"(_E)=WE\N$,?/WQ"'Y"+I,&3B#+TR*B2%[I1/X]H%.DH MV765SMF,[$ZR_ 9I?OZ>_!IHQ)F:2_29A1!6XUW--2?L;PD/?"O@B(@KU, 7 MR/?\H":?X<^'-RSI-'+]&PE>PZ8_&KS6_U8(PF:@=XQ"@PTJ]QN33=)\NR8B M1'__H2'1O8)8_E.G;SI^4#^^J1(WF0")GS&Z'^: MF"QMQDEY,<"+>09=-R-B%% =X2K2.8CMLJ9=O8X6/-[,C);.6\6X=- MY@($Y:&9O.4ADM0QMX\#Z4) MUFQ!3*B$VIE.<9KE==D,6KNKUSK:D5PZ.9>.G4MV*DBYA/ "K4 JRF9FLAEG ME^;53+4A7,>O\XI?N^UU6CO\K!D\ZYW=]GEU!'Q#0!*5^YX*29S+4+B)&H/?BOFH2?3J="J"I1L M%'[GY?&OM2R/(>?PX6AP^_GZ-X8&B>6#EUO'1WN['5T=J1C M12H\';:;NA%E-%[&Z'_T=L4XD6'+>)_#_N'"_^'.>U>,$_F_3*YSN$E^2A1-W2Q6P,8I;<5TM]["V9 M2J\L\];\3OPVN0G>:1_@FV%ZLUW I!?M(R)FE$D4P51#>E=M[0)$>G>=OBB^ M2*Y_G[A2/$X>YT!"$*:#_GS*N=J^F 'R_R#T?P!02P,$% @ C#NN6%1K MT-QK! #A, !D !X;"]W;W)K&ULK9A?C]HX M$,"_BI6K3JVT2V*3?^P!$NQN[_I0%>VVVX?J'KR)@:A)S-D&%ND^_-E.-J%- MXD"/%V(G]LQOQN,9X_&>LN]\38@ +UF:\XFU%F)S8]L\6I,,\P'=D%Q^65*6 M82&[;&7S#2,XUI.RU$:.X]L93G)K.M;O%FPZIEN1)CE9,,"W68;984Y2NI]8 MT'I]\9"LUD*]L*?C#5Z11R*^;!9,]NQ*2IQD).<)S0$CRXDU@S=SY*D)>L13 M0O;\J V4*<^4?E>=#_'$IN*![O\BI4$:,*(IU[]@7XYU+!!MN:!9 M.5D29$E>//%+Z8BC"6[7!%1.0)J[4*0I[[# TS&C>\#4:"E--;2I>K:$2W*U M*H^"R:^)G">FCVO,R+6R*P:W-).+S;%VUR+%.0?7X+%8+D"7X--&?YDI1R;B M -[>$8&3E+\;VT*B*(%V5*J=%VI1A]HA^$ASL>;@/H])_.-\6YI0V8%>[9@C MH\"/F W $%X!Y" 7?'F\ V_?O -O@ VXLI"7#X.F8>6QH=8T-'ILKCVVP <9 MH0+,&,/YBNCVM]DS%TQ&V]]M;BEDN^VRU1:\X1LLZ>^_0=_Y MPT#N5N2N2?JT6#]^!3YM!1D3 OZWN*BPH='A: MA]KSNZD_:7!_2E<*Z5L3@]=@@$/7'XV"=@:_8O!/8[A_ M(2Q*> ^%WZ"XAI[$:(<(*HC@- B9=98DZ7-%T(08.LA'[1!A!1&>ZHE-PGH0 MPB8"@L-V@%$%,/JE6+TO6J<$ZJB!%2+7#[K6!SIURG1.8WLB7"T/98"\;&29 MD6U!P4Z^5:@R)47K.B>94$N%I[,>I7=X5DCCYY2<"P<;<*XW=$=A%QRJX9 9 MKBOWK%-_*7@"$1^QHX'3$)JQ+ #3FZ6F9 MHR[ 5^A1ZU\!.H.P(X_!.M-#+H#H-1'A M(.C(@; N!]!<#\KD=P% OPF(!BCL *Q+!>RI%:;D> 'LH,VOH=>!71<7:*XN MY^3-"U@1GF5%7:&@N409,^H%L$>-U 4'7D?(H+IXH9[B]6/(]%(_$/7?3HV^ ME2=V=:[=XA1\)BQK@^Y1'H #P8P#'V3%\7$8GPPGF0N=+]SZ ZTTXS MRR_861=-9"Z:YX;=F8:9E?L_&P;#7LOJJHK,5;4G-&>K%2,K+ CX(.U('@=M&0, (@) 9 >&PO=V]R:W-H965T(9YKBTICI^E4:?R MJ14/QWOK%R9X%",F*4ED1%!FU;W)7)N) H1,<40A*A&\IQ($HTXVP'7LY4U/3"A M&FT%EU%=E;GDZF^F]&0T3PG'EHXK@3-6J&(+8M(URPD5T(*Y+1>P)7QAM+5% M(=74N63Q+4QT2C-Y#V_/49(L%^]&KE10VK0;EP!3"Q < >C ):,R%?"!)I@\ MUG=5,%5$P3ZB:=!H$+P-G3\$PB\H NOP06A8Q3EJ\%#I\I9QWCH-.9L:G(V M(_>J1R5,."=TA6;\?;(0DJM^^U&7#FN[6V];+\)3L28QCAVUR@3R+3K1FU=^ MWWO?0-ZMR+M-UB-5P7T!33).X.M&"DEHDM$5$ E37&64:F%*5 /$"+]J\V9# ML_MLH' Q[7F?D;FL@>Q5D[YF0'U5NM=S$TGO"TA]VPWX]2K]"Z3\3 MY=J*323])R2M,/0&1U#""B7\O])]L*-_J5M84S=_,#Q2MT%%.&@D_%LKG<"- MV2-5"),MOAA!3]LA"]; M[,48K3??.X#TVL->/:3O/>S67B.F;;\7HRR]/<+TVU[W".;!H>(_IQ4>M^;+ MT?MUC1#^ >\>'(X%\I6Y @B(V89*>TY67ZMKQL0>K@_3[1U%'2VJIP7DN%2J M7CM42XC;8]\*DJW-4;M@4AW<9IBJJQ)R/4']7S(F]X)V4%V^HM]02P,$% M @ C#NN6%U)C8L= P Q0L !D !X;"]W;W)K&ULQ59=3]LP%/TK5H8F)@WRU4_61FH+VY"&5%'8'J8]F.2VB4CLSG9;^/>[ M=M*0EA -J8B7UG;N/3[W^,8Y@PT7]S(&4.0A2YD<6K%2RS/;EF$,&96G? D, MG\RYR*C"J5C8 M&&U,-E:3,'V,,R7P:8)Y*IC%5,")%B(B$YYA=TAJ])VFE$ER0F;Y^1(^)S/% MPWLR?AY[\:#'0([/0=$DE9\P[W9V3HZ//I$CDC!R$_.5I"R2 ULA:;VU'18$ MQSE![P6"/KGB3,627+ (HMU\&XLM*_:V%8^]1L K*DZ)[WXFGN.U:OA,_C_= M;Z#CEP?@&SR_Z0#J1!T)0=D"\)519/Q(JG%3^FB61QLJ(O+[!T*22P69_%.G M;[Y_JWY_?4V&DN]<'546Q$>NTI'0ALI^A.673GG1NZIZWEY#U\2T7FCH7DFXUTCX&S 02%GW\RC"SU$BE:#Z0UQ'LA'KM>=T M(+"=LOMEV?UW;NG^(:4Z$-B.5*[S9"B<-VKJ KAZ!7<OK>V* M(WB MBR9RSYA/%%\:VW7'%9HX,XS19X/0 ?A\SKG:3O0&I7,/_@%02P,$% @ MC#NN6.E1Q=&N#@ BYL !D !X;"]W;W)K&UL MM9U;;]LX&H;_"I'9';1 -K$DRTX[:8 T.C"#=B;;=G8N!GO!R+0M5 =7AZ0! M^N.'E&3+M!DZVGW=BS16Q.>CJ%?Z2+X2??F8%U_+)><5^9XF6?GN9%E5J[?G MYV6TY"DKS_(5S\1?YGF1LDI\+!;GY:K@;-842I-S>S2:G*5*ZHE\*5A6LD95)?D7N9[-8OD[2\AMUEXG4F^O/%ZQ."E? MBUW^^.R15_]X?7E>BV2/=0UB+OZ1%6?$L9XM[IF+_\JR M37%'UYS_7_3@Y<5UT4-S<8]'QN+TY<5MPYET-A>%T_"N#V)7<5CPM M_ZNIY_N6.]9S91YZ6ZY8Q-^=B$13\N*!GUS]_),U&?VBTPL2YB%A/A(6(&$A M$D9!,$6#XXT&QR;ZE5=S4N6B>]!*<26D&/-2ISDC9ZCF6MBD@^MG,@/\I%]C],ZU>G)"!JJ M)R3,0\)\)"Q PD(DC()@BN@N-J*[.%(__ *I023,0\)\)"Q PD(DC()@B@;? M;#3XY@4WOC:/GI('7E9QMB K7L2Y-IL::4.5AX1Y2)AO;K0Q>>*LT(U6 F0M M0B2,@F"*RJQ1/P\W&I9@X^RY!&LF#=48E.9!:3Z4%D!I(91&4315?5NSP-:1 M,FT'1HD12?.@-!]*"Z"T$$JC*)HJ1KL7HPU-N6;<8 DB:1Z4YA]H..?YM NM M1PBE411-E5L_V6\9YW'5>Y]67]!9?2C-@])\*"V TD(HC:)HJN;ZR7UK?*Q\ M"YWNA](\*,V'T@(H+832*(JFBK%W&"RSQ?!RJ\D,&BR^_55H%0OT(*,V#TOP#[68:H4+]!RB-HFBJVGH+PC)/IW=JF^<%N2\X MBY92>"OV).5&\OLD7C0/9NJ[;%!# DKSH#3_0"..73)C3WKI04T)*(VB:.HC MK;TM89MMB2^\2.-,)-[]&YUA1LX,'2HZ*,V#TOP#S?=F]*SHH/4(H32*HJFB MZ]T(VSC!O.GJK9JN7M5W]4[)C)=1$3=3PUKA0=T(*,V#TOP#3?AER7-Z/<;7,ZXI$K!;;ZY7H M:7=R_OFG"]N:_D)6XOHOR&,15Q7/Y$.)@B%G$MJQX1GQ!8$7W6E4:Q'/944* M3I:L)/=<%&=B#_'W6#[IV":YQV4L?LH=!+K=*:H+H0M9LWA3&_)*5**[NQ_. MD:_E]H)'/'Z0KD)9BSW;FI]IKU*H30.E411-O4I[F\8VNPVWF3A=4:$F=14L_$:1*GB']?255I+U6H:P.E>5":W]&VYYML>[H_VZ39SQE-]O8+ MH;6C*)JJHMY]LVSSOQ;'8O;1\G%M1_+ MB4E2YDDCKF\U2^)Y+)0V%S>5+!+7LU9H;04L:ZM=1V<7:J/>F*LY6$!06P9* M"Z"T$$JC*)HJQMZ6L8TS[5?_WE=4D[.T(RLS2U_7VZS)O_RAR4ISD?0T(CYM M]A&IMZQ$9FZ\[\U+ "S-Z[9HD\=SD4I725T2%D5%+2 RE=?9BL7R"A%5YV4E M+Z@D.26LZA+S.GVO7R ]);Q-U/<"UI8D\SI)B,BE49X]\*)J[N8BLZ\OQO;I MVU[1OZ0'1E&HB7+%NO 59$G M;:NO^TR/L3A^T7WHFDRTZ[KJFX.6AV2=N:2*4Q&WJ>3F-(E/F7(&ZVPFCF!S MSN1I:@YQJTVD'+JSN#EU>YPX3?DL%DV6/'7=KZ[YHR0OY0[RV7_9I]D[OC.B MS9M0 Q!*\Z&T $H+H32*HJFWO=X M,T&8._ED!_DKBZ$=I21P ]Q632W@?@^ MX>2NR-.X+//BJ=&R]M8(]0FA- ]*\Z&T $H+H32*HJD:[?U&>W(D^\>&>I%0 MF@>E^5!: *6%4!I%T50Q]EZD;7X;:OMV../W%1'W0Y&W3_&>=IW M'&_,E1@L-:C3"*4%4%H(I5$4395:[S3:9L=L5VJB'Y]EL@>ZZ2,6[)DD?*$; M]X[L795I=[-V7HOTS-4<+!_HFTM06@BE411-E4]O'=IFUVM?/HIN#*-;,_=6 M&5QV Y=F6-/.UQ!FZM >;4<[V!_QH&']CG9P?8D &C:$TBB*INJG-TH= ML\LW:'$0,VNP:JR7G3X/&M9_:=@ &C:$TBB*IJJF-^XTW6FF MW=P+-4"@-(JBJ<+J#1#'_,+5.KOVS]]V#]P]_QBNF3A875#G TKS#[3=Y/G' M<*'U"*$TBJ*IBNM=#L?L99#SCQW2M1.&YJ1@R4'=4"@-!]*"Z"T M$$JC*)HJP]X!<8ZU"IP#?>T*2O.@-!]*"Z"T$$JC*)HJQMY/<0XL!_<_9&'H M&UA0F@>E^0?:SC%D8:A' *51%$U=!KSW",9FCT#)PN_K4ORY+#QK!I%S-LL "A[QY!:7Y'4Z9=K+.1N_N]"E#/ M TJC*)JJK-[S& _P/#Z) *R(EL8QL!DX6%U0BP-*\Z&T $H+H32*HJDBW/HR MF&-9'&.HQ0&E>5":#Z4%4%H(I5$4315C;W&,D1:'&398@%"+ TKSQQJ+P]JS M.* Q0RB-HFBJL'J+8WQ@3;DJ85E%;L3V.&()^5#-R%\?N?Q.&_V]#>IO0&D> ME.9#:0&4%D)I%$53)=A['N-CK3(WACH?4)H'I?E06@"EA5 :1=%4,?;.Q]C\ M[H??KIY1DGF1I]OKX)3M@^C;*[9J5ZXV\P=K$FJ 0&D^E!9 :2&41CN:LIJ( MJSP JZJMMS;&YNGY/_/B*\D+^9YZNSZ.?&]>"N^PS* .1T=3EN>=["^7XD&C M^B^,&D"CAE :1='4+ZKLG0KW@%-AZ+YMSYU(R\+C#SS)5\\])6J.-%114)H' MI?E06@"EA5 :1=%4=?9VA7LLN\*%VA50F@>E^5!: *6%4!I%T50Q]G:%:[8K M-O?(8GU3+ T3RF;88 %"[0HHS7?WWPJQ',VW_^[O9MO["Z5!ZT91-%4RO0_A MFGV(/_-D?DK"@O-L'O-D1GYFZ>H7\IE%R_*4W)W=Z%XS?6^&#I8.U(N TGPH M+8#20BB-HFBJ$'LOPCV6%^%"O0@HS8/2?"@M@-)"*(VB:*H8>R_"-7L1'_A" M9-%U\B1SKGUUT0P9+#RH!P&E^>[^=]OHEAK5[.9<:!(HU%U T52I].Z":W87 MO.*,O*]YDF@5 K42H#0/2O.AM !*"Z$TBJ*I>NNM!/=85H(+M1*@- ]*\Z&T M $H+H32*HJEB[*T$]] R4JGT$MH5NN4K_UK=0>T"*,V#TGPH+8#20G=_@M]R M]U>XH*BHJJ)ZN\ UVP6;=$I^$.7+R[7*@CH$4)H'I?E06@"EA5 :1=$4_4UZ MMV$R.E)ZG4#-!2C-@])\*"V TD(HC:)HJAA[G9"&$*62JU2'45X#2O,G^.DO.U-W-03XT: "EA5 :1=%:@9V72\XKCU7L MZC+EQ8+?B$1:DDBN^":#;&TE!9_+KXA[>VV?G.]MO['>>I9FNV^]#73;0^LM M;;:?]V&O+E=LP3^R8A%G)4GX7%1A=#85Y[Z(%\O-ARI?O3L1K7"?5U6>-K\N M.9OQ0NX@_C[/\VK]009XS(NOS6%>_0U02P,$% @ C#NN6!# &[MD @ M4 8 !D !X;"]W;W)K&ULQ55?;]HP$/\JIZR: M6FDC$"#=6(A40'256@D5M7N8]F"2 ZPZ=F8[T'W[G9TT8A-ETJ1I+\2^^'Y_ M[O EV2O]9+:(%IX+(:!*[\_[ (\>].5B#<[)2ZLEM;O)QT'6" M4&!F'0*CQPZG*(0#(AG?&\R@I72)A^L7]+GW3EY6S.!4B2\\M]MQ\"& '->L M$O9>[3]CXV?H\#(EC/^%?7WV,@X@JXQ519-,"@HNZR=[;NIPD!!%KR1$34+D M===$7N6,698F6NU!N].$YA;>JL\F<5RZIBRMIK><\FPZ9US#(Q,5PATR4VFD MBEMX#U=YSEW=F( ;63??5?%\AI9Q82[@#+B$.RX$A4T26A+C(,.L(9[4Q-$K MQ'=,=Z#?>P=1-QK PW(&YV<7O\*$Y*4U%+6&(H_;_[.A"1-,9@A+_^^^UJHJ MN=S G$L*L=/8,?+TE/+BAL/EVS%1-/CA.[F[0R)0LPW% 5\2@ MWF&0OGW3B[N?3ECKM];ZI]#3A>:DNR3AJ\:96H-4%H\)K:%B#^5NYBX=)N'N M"/N@91^<9+_%'0J(CG&=3/S+H@Q;6_A/[ 6M];BDQ7WUG;>VHE&UQ@? M#QH]Z$2_M3H\&!!NUM+EVW!R+W!-6=W.)=G4]?RJ-U:5?F:LE*4)Y)=;&OFH MW0%ZOU:DIMFX,=1^1-*?4$L#!!0 ( (P[KEB/1#C_ 0, *L) 9 M>&PO=V]R:W-H965TM<9=,@)..YKI4%CTPGNMW?:/WKGR9D%,WBAQ%>>V?4T& >0X9*5PMZH M[2>L'1HZ?:D2QC]A6\^- DA+8U5>"Q-!SF7U9@]U(/8$^B?/",2U0.RY*T.> M\I)9EDRTVH)VLTF;:WA7O33!<>E696XU?>4D9Y-YN3!X7Z*T\&%#3P/OX"S+ MN L9$W EJX5W 3RX1,NX,&]IRN]B\!I",&NFT0"7<"NY-8 MALO<33(\&D_"30O8H $;=(+-K4KO8+:#.B-,I/RU;>8[-;TP@,.&<_AW5WOX M#V!'#>RH.ZA,H%M4XX)["%8S:5A5T#+: VVXW0IW2>6SJ@/PN $\?M&JPP^X M4'E.G'Y&&VBGXA?&==Q@C__N)AC_ ]B3!O;D#U->EOD"M=\0=;$UIL0,F,S M*)%1U-NJ8N5"962XE_.#T2"B7WO>]Z*G,R3JY)O]4HB@($)/031/Y;JU_E=Z MQWM(O:-X^ S/WIG6^P\ELC;272/#O:/776.NF5YQ:4#@DJ2BHV,*MZYN!E7' MJL*?Q@MEZ6SWS37=IE"["?1]J93===P!W]S/DI]02P,$% @ C#NN6'>( MG8 N P #A, T !X;"]S='EL97,N>&ULW5A=;]HP%/TKD;M.K30U0$9* M5D#:D"I-VJ9*[*D,RL]7AYLQN_J(!+$GI)NP>07K7@0JD=C G$APGL8\>HKP^BWL., M$?>VB:O1YY;'Y9U7:6&]:<-^IN1Z[R+B I:7YBQXHF) 1E3PL>:0E=&Z9)U0W:S(6.F4Z4:F35:A85^P M#.QH/IW!W:@B!- 8E=M&RNE425IY6&74#4L[84+ZS?HL9OLGH+) M^!1,GD!-1LGQ>ZS/0T=G,JS?WQN'A*TC0A,-X"@V(#_@2"?6HL%XSH7ALN[- M>)HR^>JD8.D-'=O#_A:_'9^RC,Z%>6C 5FWO[.4S_.D&74'"U&/6K>_P?3: M<7,.M%IP'(?Y$< P'FA.2[+AXRJ#Z;CSTGLY9]IDD11'&,K.AIY'8RP=8MC M^/K9,&^0@>F TI^M-;[;>(7LKP-L3_=5"#93O!*QF>)K#8A_W2 C2?R[C>E M!K8+6.V OE\':LJ?$T6PJY@W[ G&D23!$*A%?XW&,;(Z,7S\^X,])5&4)'X$ M,+^#*,(0>!IQ!', 'C DBJKWX,[[*%R]I\+U+V##%U!+ P04 " ",.ZY8 MEXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S M9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X M 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7) MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 M ( (P[KEAV(IA\F , /L9 / >&PO=V]R:V)O;VLN>&ULQ9E=;],P M%$#_BI4G>!AMG&W 1)'V"9,&5"O:*W+CV]6:8W>VTP&_GNM$!6<;5[R8/-5Q M'/?D.K['3MX]6'>WM/:.?6^T\;-B'<+F:#+Q]1H:X5_9#1@\L[*N$0$/W>W$ M;QP(Z=< H=$3/IT>3AJA3/'^W:ZON9ND!S9 '90U6!DK;A0\^#_GXR';*J^6 M2JOP8U9T90T%:Y11C?H)JG-4'H1>VLUK.B[$_<@ NJ?E*] MB)!?Q=)W-4$LKP6"S(K#*7:X4LZ'KD77OT#&+6#C_J@-]D+I .Y,!/C@;+M1 MYC9V@W-)Z9<#[+H]?J?M624SE:?J> M4OE[FI=NH6Z-PK8"17-V5]]RRRQ5H, M'K^2$E%?*S&*Y$,JQ&Z%;8)] Q$0=+TCI**&4F8V"LHOY!]PDN! 0 *1< !H !X M;"]?1/L:O"[1N%1?A0%]T@SRJRHXS?U:/(VR]7Y>'2-KZ\=#ZYU57C M,U.&T'U8ZXO2U;F?M9UKAC>GMJ_S,"S[L^WRXIJ?G>4T7=K^>8;9;9]G)H=[ MY_XSL3V=+H7[;(OOVC7AC\'VI^VOOG0NF.20]V<7,F-OU;3M[?B@V3#9)/MC M9OK]D8R-'<00Q/&#!((D?M <@N;Q@Q80M(@?M(2@9?R@%02MX@>M(6@=/V@# M09OX092BC*F"I!>L%6A-R#4I\)H0;%(@-B'9I,!L0K1)@=J$;),"MPGA)@5R M$])-"NPFQ)L4Z,VH-RO0FU%O5J WO_QL*]";46]6H#>CWJQ ;T:]68'>C'JS M KT9]68%>C/JS0KT9M2;%>@MJ+HD!O>;DL4:"WH-ZB0&]! MO46!WH)ZBP*]!?46!7H+ZBWOU-N'>^7\U/-8X_GOI#H,W[KI^''YV$0)YR/. M%F[&=[]02P,$% @ C#NN6&/6BA2; 0 E!< !, !;0V]N=&5N=%]4 M>7!E&ULS9C-;L(P$(1?)^@)ML2$026[:A\/9U MPH_4BD8@*G4NL1+OSHR]TG?(Y'UKR$6;NFK<-"Z\-X^,N;2@6KE$&VK"3JYM MK7QXM0MF5+I4"V)B-!JS5#>>&C_TK48\FSQ3KE:5CUXVX;,K=3.-+54NCIYV MA:W7-%;&5&6J?-AGZR;[X3+<.R2ALZMQ16G<(!3$[*1#N_.[P;[O;4W6EAE% M=YF5*FTU4=6A)G+*G,%42^KI*=Z*#?V8<; MIMV37^W?R?09ALJYU<:%B5FZW.XPDK9[:((065_V'_'H&*2O/A^UT\XH.],[ M7.^GMLMN'HYUR_5W_'W&1_T+Y!&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( (L[KEA,HK2* M!P8 +0@ 8 " @0X( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ BSNN M6%N7W#V_ @ 1@< !@ ("!&!0 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ C#NN6+XSN!GB!@ AAX !@ M ("!UR, 'AL+W=OM'0( +$$ 8 " @>\J !X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L! A0#% @ C#NN6";:+PY$ @ B@8 !@ ("!N2\ M 'AL+W=O&UL4$L! A0#% @ C#NN6*YTL_?U!@ :A$ !D M ("!N3L 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ C#NN6+CN?!6D P *0@ !D ("!.TD 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ C#NN6)) M%G1" P :@< !D ("!!V, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C#NN6$)AB_P, P L08 !D M ("!8FX 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ C#NN6 4^#)!^ @ P04 !D ("! MG'H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ C#NN6*K1B$': @ T H !D ("!G80 'AL+W=O&PO=V]R:W-H965T<[M]/0, #D. 9 " @?22 !X;"]W;W)K&UL4$L! A0#% @ C#NN6+$\PC2U! 31@ !D M ("!:)8 'AL+W=O&PO=V]R M:W-H965T'@=M&0, (@) M 9 " @?:? !X;"]W;W)K&UL M4$L! A0#% @ C#NN6%U)C8L= P Q0L !D ("!1J, M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MC#NN6(]$./\! P JPD !D ("!&K@ 'AL+W=O&UL+G)E;'-02P$"% ,4 M " ",.ZY88]:*%)L! "4%P $P @ $2Q0 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 +@ N 'D, #>Q@ ! end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 75 194 1 false 32 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Sheet http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995455 - Disclosure - Business and Liquidity Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidity Business and Liquidity Notes 10 false false R11.htm 995465 - Disclosure - Significant Accounting Policies Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 11 false false R12.htm 995475 - Disclosure - Net Loss Per Share Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShare Net Loss Per Share Notes 12 false false R13.htm 995485 - Disclosure - Cash and Cash Equivalents Sheet http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalents Cash and Cash Equivalents Notes 13 false false R14.htm 995495 - Disclosure - Accrued and Other Current Liabilities Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities Accrued and Other Current Liabilities Notes 14 false false R15.htm 995505 - Disclosure - Share-based Compensation Plans Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlans Share-based Compensation Plans Notes 15 false false R16.htm 995515 - Disclosure - Related Party Transactions Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 995525 - Disclosure - Fair Value Measurement Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurement Fair Value Measurement Notes 17 false false R18.htm 995535 - Disclosure - Contingencies Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureContingencies Contingencies Notes 18 false false R19.htm 995545 - Disclosure - Recent Accounting Pronouncements Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 19 false false R20.htm 995555 - Disclosure - Subsequent Events Sheet http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 20 false false R21.htm 995565 - Disclosure - Significant Accounting Policies (Policies) Sheet http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureSignificantAccountingPolicies 21 false false R22.htm 995575 - Disclosure - Net Loss Per Share (Tables) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShare 22 false false R23.htm 995585 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalents 23 false false R24.htm 995595 - Disclosure - Accrued and Other Current Liabilities (Tables) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables Accrued and Other Current Liabilities (Tables) Tables http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities 24 false false R25.htm 995605 - Disclosure - Share-based Compensation Plans (Tables) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables Share-based Compensation Plans (Tables) Tables http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlans 25 false false R26.htm 995615 - Disclosure - Business and Liquidity - Additional Information (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails Business and Liquidity - Additional Information (Details) Details 26 false false R27.htm 995625 - Disclosure - Significant Accounting Policies - Additional Information (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails Significant Accounting Policies - Additional Information (Details) Details 27 false false R28.htm 995635 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails Net Loss Per Share - Schedule of Anti-dilutive Securities (Details) Details 28 false false R29.htm 995645 - Disclosure - Cash and Cash Equivalents - Summary of Cash Equivalents (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails Cash and Cash Equivalents - Summary of Cash Equivalents (Details) Details 29 false false R30.htm 995655 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued liabilities (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails Accrued and Other Current Liabilities - Summary of Accrued liabilities (Details) Details 30 false false R31.htm 995665 - Disclosure - Accrued and Other Current Liabilities - Additional Information (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails Accrued and Other Current Liabilities - Additional Information (Details) Details 31 false false R32.htm 995675 - Disclosure - Share-based Compensation Plans - Additional Information (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails Share-based Compensation Plans - Additional Information (Details) Details 32 false false R33.htm 995685 - Disclosure - Share-based Compensation Plans - Summary of Option Activity (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails Share-based Compensation Plans - Summary of Option Activity (Details) Details 33 false false R34.htm 995695 - Disclosure - Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details) Details 34 false false R35.htm 995705 - Disclosure - Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details) Details 35 false false R36.htm 995715 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 36 false false R37.htm 995725 - Disclosure - Fair Value Measurement - Additional Information (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails Fair Value Measurement - Additional Information (Details) Details 37 false false R38.htm 995735 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 38 false false All Reports Book All Reports inkt-20240331.htm inkt-20240331.xsd http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 false false JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "inkt-20240331.htm": { "nsprefix": "inkt", "nsuri": "http://minktherapeutics.com/20240331", "dts": { "inline": { "local": [ "inkt-20240331.htm" ] }, "schema": { "local": [ "inkt-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] } }, "keyStandard": 165, "keyCustom": 29, "axisStandard": 16, "axisCustom": 0, "memberStandard": 15, "memberCustom": 16, "hidden": { "total": 6, "http://fasb.org/us-gaap/2023": 2, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 75, "entityCount": 1, "segmentCount": 32, "elementCount": 414, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 253, "http://xbrl.sec.gov/dei/2023": 31, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "unique": true } }, "R3": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "longName": "100040 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_bb6e0676-682b-4ac8-948a-77856da43049", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bb6e0676-682b-4ac8-948a-77856da43049", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_66081bd9-efd2-4fdc-bd8e-acce17f939a0", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidity", "longName": "995455 - Disclosure - Business and Liquidity", "shortName": "Business and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "inkt:BusinessAndLiquidityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "inkt:BusinessAndLiquidityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureSignificantAccountingPolicies", "longName": "995465 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShare", "longName": "995475 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalents", "longName": "995485 - Disclosure - Cash and Cash Equivalents", "shortName": "Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities", "longName": "995495 - Disclosure - Accrued and Other Current Liabilities", "shortName": "Accrued and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlans", "longName": "995505 - Disclosure - Share-based Compensation Plans", "shortName": "Share-based Compensation Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "longName": "995515 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurement", "longName": "995525 - Disclosure - Fair Value Measurement", "shortName": "Fair Value Measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureContingencies", "longName": "995535 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRecentAccountingPronouncements", "longName": "995545 - Disclosure - Recent Accounting Pronouncements", "shortName": "Recent Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEvents", "longName": "995555 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies", "longName": "995565 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareTables", "longName": "995575 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsTables", "longName": "995585 - Disclosure - Cash and Cash Equivalents (Tables)", "shortName": "Cash and Cash Equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables", "longName": "995595 - Disclosure - Accrued and Other Current Liabilities (Tables)", "shortName": "Accrued and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables", "longName": "995605 - Disclosure - Share-based Compensation Plans (Tables)", "shortName": "Share-based Compensation Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails", "longName": "995615 - Disclosure - Business and Liquidity - Additional Information (Details)", "shortName": "Business and Liquidity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995625 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "shortName": "Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1feb960d-26a7-40dc-b1ed-95f38104e5b3", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "unique": true } }, "R28": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails", "longName": "995635 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)", "shortName": "Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_7e2bce03-28dd-41db-8ef7-f9531f63017a", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7e2bce03-28dd-41db-8ef7-f9531f63017a", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails", "longName": "995645 - Disclosure - Cash and Cash Equivalents - Summary of Cash Equivalents (Details)", "shortName": "Cash and Cash Equivalents - Summary of Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_597e3d4e-5c8f-46d7-be19-3c8591ef6c70", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_597e3d4e-5c8f-46d7-be19-3c8591ef6c70", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails", "longName": "995655 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued liabilities (Details)", "shortName": "Accrued and Other Current Liabilities - Summary of Accrued liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails", "longName": "995665 - Disclosure - Accrued and Other Current Liabilities - Additional Information (Details)", "shortName": "Accrued and Other Current Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6acd60fc-fee8-488d-aba8-7a92116c61d9", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "unique": true } }, "R32": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "longName": "995675 - Disclosure - Share-based Compensation Plans - Additional Information (Details)", "shortName": "Share-based Compensation Plans - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails", "longName": "995685 - Disclosure - Share-based Compensation Plans - Summary of Option Activity (Details)", "shortName": "Share-based Compensation Plans - Summary of Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_b49377d5-9ef0-4c30-8ff1-e76e32c459e5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b49377d5-9ef0-4c30-8ff1-e76e32c459e5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails", "longName": "995695 - Disclosure - Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)", "shortName": "Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_b49377d5-9ef0-4c30-8ff1-e76e32c459e5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b49377d5-9ef0-4c30-8ff1-e76e32c459e5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails", "longName": "995705 - Disclosure - Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details)", "shortName": "Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b89b164d-84b9-4c98-a064-a7036a4e4c10", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "995715 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "inkt:DueToRelatedParty", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_43cfeccd-1a27-4a6c-8c1f-727ead1251ed", "name": "inkt:PeriodOfLicenseAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "unique": true } }, "R37": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails", "longName": "995725 - Disclosure - Fair Value Measurement - Additional Information (Details)", "shortName": "Fair Value Measurement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_15168398-c8ef-444c-87b2-9434b972a076", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b447d00d-3dae-4ac3-a0fe-2a80b077bf36", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "unique": true } }, "R38": { "role": "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "995735 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_18f96ab3-117a-4eaf-8543-027f7e08d9c9", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "inkt:BusinessAndLiquidityTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d6376157-1c92-427e-9d4f-36f47ce0a191", "name": "us-gaap:SaleOfStockTransactionDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "inkt-20240331.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and Other Current Liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15", "r475" ] }, "inkt_AccruedAndUnpaidInterestBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "AccruedAndUnpaidInterestBalance", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and unpaid interest balance", "label": "Accrued and Unpaid Interest Balance", "documentation": "Accrued and unpaid interest balance." } } }, "auth_ref": [] }, "inkt_AccruedContractManufacturingExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "AccruedContractManufacturingExpenseCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract manufacturing costs", "label": "Accrued Contract Manufacturing Expense Current", "documentation": "Accrued contract manufacturing expense current." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18" ] }, "inkt_AccruedResearchServicesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "AccruedResearchServicesCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research services", "label": "Accrued Research Services Current", "documentation": "Accrued research services current." } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll", "label": "Accrued Salaries, Current", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18", "r458" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "terseLabel": "Equipment, net of accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r34", "r98", "r366" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r25", "r26", "r65", "r101", "r363", "r378", "r381" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r26", "r286", "r289", "r320", "r374", "r375", "r566", "r567", "r568", "r573", "r574", "r575" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r525" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r60" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r267", "r268", "r269", "r389", "r573", "r574", "r575", "r609", "r624" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r531" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r531" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r531" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r531" ] }, "inkt_AdjustmentToAdditionalPaidInCapitalIssuanceOfRelatedPartyNote": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "AdjustmentToAdditionalPaidInCapitalIssuanceOfRelatedPartyNote", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of related party note (Note 8)", "label": "Adjustment to additional paid-in capital issuance of related party note", "documentation": "Adjustment to additional paid-in capital issuance of related party note." } } }, "auth_ref": [] }, "inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Grant and recognition of stock options", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition", "documentation": "Adjustments to additional paid in capital share based compensation stock options grant and recognition." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of parent stock options", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "inkt_AgenusIncMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "AgenusIncMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agenus Inc", "label": "Agenus Inc [Member]", "documentation": "Agenus Inc." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r496", "r507", "r517", "r542" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r499", "r510", "r520", "r545" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r531" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r538" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r503", "r511", "r521", "r538", "r546", "r550", "r558" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r556" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r262", "r270" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total anti-dilutive securities", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r154" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r32" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r277" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r81", "r99", "r123", "r159", "r164", "r168", "r173", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r279", "r283", "r301", "r359", "r412", "r475", "r487", "r578", "r579", "r612" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r95", "r104", "r123", "r173", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r279", "r283", "r301", "r475", "r578", "r579", "r612" ] }, "inkt_AtlantClinicalLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "AtlantClinicalLtdMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Atlant Clinical Ltd [Member]", "label": "Atlant Clinical Ltd [Member]", "documentation": "Atlant Clinical Ltd." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r553" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r554" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r549" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r549" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r549" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r549" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r549" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r549" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r552" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r551" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r550" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r550" ] }, "inkt_BusinessAndLiquidityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "BusinessAndLiquidityAbstract", "lang": { "en-us": { "role": { "label": "Business And Liquidity [Abstract]", "documentation": "Business and liquidity." } } }, "auth_ref": [] }, "inkt_BusinessAndLiquidityDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "BusinessAndLiquidityDisclosureLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business and Liquidity Disclosure [Line Items]", "documentation": "Business and Liquidity Disclosure." } } }, "auth_ref": [] }, "inkt_BusinessAndLiquidityDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "BusinessAndLiquidityDisclosureTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business And Liquidity Disclosure [Table]", "documentation": "Business And Liquidity Disclosure." } } }, "auth_ref": [] }, "inkt_BusinessAndLiquidityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "BusinessAndLiquidityTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidity" ], "lang": { "en-us": { "role": { "terseLabel": "Business and Liquidity", "label": "Business And Liquidity [Text Block]", "documentation": "Business and liquidity." } } }, "auth_ref": [] }, "inkt_BusinessServicesAndOccupancyCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "BusinessServicesAndOccupancyCostsMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Services and Occupancy Costs", "label": "Business Services And Occupancy Costs [Member]", "documentation": "Business Services and Occupancy Costs." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r28", "r97", "r456" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r97" ] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r97", "r361" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total", "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r28", "r72", "r121" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r72" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cost", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r565", "r622" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures - non-cash activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r529" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "inkt_ClinicalResearchServices": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ClinicalResearchServices", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical research services", "label": "Clinical Research Services", "documentation": "Clinical research services." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r530" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r530" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r23", "r52", "r360", "r399" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r477", "r478", "r479", "r481", "r482", "r483", "r484", "r573", "r574", "r609", "r623", "r624" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r59", "r400" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.00001 per share; 150,000,000 shares authorized; 34,699,056 and 34,599,119 shares issued at March 31, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r59", "r362", "r475" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r535" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r534" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r536" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r533" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r27", "r107", "r109", "r114", "r355", "r371" ] }, "inkt_ConvertibleAffiliatedNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ConvertibleAffiliatedNoteMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Affiliated Note", "label": "Convertible Affiliated Note [Member]", "documentation": "convertible affiliated note." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Convertible debt outstanding amount", "terseLabel": "Outstanding principal amount of Note", "label": "Convertible Debt", "totalLabel": "Convertible Debt, Total", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r14", "r83", "r621" ] }, "inkt_ConvertiblePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ConvertiblePromissoryNoteMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Promissory Note", "label": "Convertible Promissory Note [Member]", "documentation": "Convertible promissory note." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r14", "r55", "r56", "r82", "r83", "r126", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r314", "r462", "r463", "r464", "r465", "r466", "r570" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding principal amount of Note", "terseLabel": "Principal balance of note", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r48", "r49", "r202", "r314", "r463", "r464" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt, annual interest rate", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r20", "r48", "r214" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r20", "r48", "r219", "r314" ] }, "us-gaap_DebtInstrumentInterestRateTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateTerms", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt, interest rate terms", "label": "Debt Instrument, Interest Rate Terms", "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets." } } }, "auth_ref": [ "r20" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt issued, principal amount", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r383" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r126", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r314", "r462", "r463", "r464", "r465", "r466", "r570" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r21", "r126", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r314", "r462", "r463", "r464", "r465", "r466", "r570" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r21", "r35", "r36", "r47", "r48", "r49", "r53", "r77", "r78", "r126", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r314", "r462", "r463", "r464", "r465", "r466", "r570" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r33" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Plans", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r232", "r235", "r263", "r264", "r266", "r472" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r491" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r524" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "inkt_DrBuellMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "DrBuellMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Dr. Buell.", "label": "Dr. Buell [Member]", "terseLabel": "Dr. Buell" } } }, "auth_ref": [] }, "inkt_DueToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "DueToRelatedParty", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Due to related parties", "label": "Due To Related Party", "documentation": "Due to related party." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Per common share data:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "terseLabel": "Basic net loss per common share", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r115", "r136", "r137", "r138", "r139", "r140", "r147", "r149", "r151", "r152", "r153", "r157", "r294", "r295", "r356", "r372", "r459" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss per common share", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r115", "r136", "r137", "r138", "r139", "r140", "r149", "r151", "r152", "r153", "r157", "r294", "r295", "r356", "r372", "r459" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r146", "r154", "r155", "r156" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r305" ] }, "inkt_EmployeeBonusMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "EmployeeBonusMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Bonus", "label": "Employee Bonus [Member]", "documentation": "Employee Bonus." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period of unrecognized share-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r265" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense related to non-vested shares", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r608" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense related to stock options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r608" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock [Member]", "terseLabel": "2021 Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock Options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r489" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r489" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r564" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r489" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r563" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r489" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r489" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r489" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r489" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r92", "r110", "r111", "r112", "r127", "r128", "r129", "r133", "r141", "r143", "r158", "r174", "r177", "r220", "r267", "r268", "r269", "r272", "r273", "r285", "r286", "r287", "r288", "r289", "r291", "r293", "r306", "r308", "r309", "r310", "r311", "r312", "r320", "r374", "r375", "r376", "r389", "r442" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r532" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r496", "r507", "r517", "r542" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r493", "r504", "r514", "r539" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r538" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value By Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r44", "r45", "r46" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r210", "r224", "r225", "r226", "r227", "r228", "r229", "r300", "r333", "r334", "r335", "r463", "r464", "r468", "r469", "r470" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurement" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r299" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r210", "r224", "r229", "r300", "r334", "r463", "r464", "r468", "r469", "r470" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r210", "r224", "r225", "r226", "r227", "r228", "r229", "r333", "r334", "r335", "r463", "r464", "r468", "r469", "r470" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Option", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r7", "r13" ] }, "inkt_ForgivenessOfRelatedPartyLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ForgivenessOfRelatedPartyLiabilityMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Forgiveness of related party liability member.", "label": "Forgiveness of Related Party Liability [Member]", "terseLabel": "Forgiveness of Related Party Liability" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r500", "r511", "r521", "r546" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r500", "r511", "r521", "r546" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r500", "r511", "r521", "r546" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r500", "r511", "r521", "r546" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r500", "r511", "r521", "r546" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r69", "r422" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r67" ] }, "inkt_ImpactOfChangeInFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ImpactOfChangeInFairValueDisclosure", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of change in fair value", "label": "Impact Of Change In Fair Value Disclosure", "documentation": "Impact of change in fair value disclosure." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r180", "r181", "r427" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r181", "r427" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities and other current liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total", "negatedLabel": "Other operating assets and liabilities", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r503", "r511", "r521", "r538", "r546", "r550", "r558" ] }, "inkt_IndividualServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "IndividualServicesMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Individual Services", "label": "Individual Services [Member]", "documentation": "Individual Services." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r556" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r492", "r562" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r492", "r562" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r492", "r562" ] }, "inkt_IntercompanyAllocationIncludedInExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "IntercompanyAllocationIncludedInExpense", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intercompany allocation included in expense", "label": "Intercompany Allocation Included in Expense", "documentation": "Intercompany allocation included in expense." } } }, "auth_ref": [] }, "inkt_InterestAccruedOnRelatedPartyNote": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "InterestAccruedOnRelatedPartyNote", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest accrued on related party note", "label": "Interest accrued on related party note", "documentation": "Interest accrued on related party note." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income, net", "totalLabel": "Interest Income (Expense), Net, Total", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r87" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r116", "r119", "r120" ] }, "inkt_IssuanceOfRelatedPartyNote": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "IssuanceOfRelatedPartyNote", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of related party note (Note 8)", "label": "Issuance of related party note", "documentation": "Issuance of related party note." } } }, "auth_ref": [] }, "inkt_IssuanceOfStockOptionsForPaymentOfCertainEmployeeBonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "IssuanceOfStockOptionsForPaymentOfCertainEmployeeBonuses", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of stock options for payment of certain employee bonuses", "label": "Issuance Of Stock Options For Payment Of Certain Employee Bonuses", "documentation": "Issuance of stock options for payment of certain employee bonuses." } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Legal Fees", "terseLabel": "Legal services fee", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r68" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r64", "r85", "r365", "r475", "r571", "r576", "r610" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r19", "r96", "r123", "r173", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r280", "r283", "r284", "r301", "r475", "r578", "r612", "r613" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increasing amount of borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r16" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Category of Item Purchased", "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Purchase Commitment, Category of Item Purchased", "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LossContingencyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAbstract", "lang": { "en-us": { "role": { "label": "Loss Contingency [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDisclosures": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyDisclosures", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made." } } }, "auth_ref": [ "r182", "r183", "r184", "r186", "r188", "r189", "r190", "r191" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r185", "r187", "r188", "r189", "r231", "r337", "r373", "r391", "r392", "r448", "r449", "r450", "r451", "r452", "r454", "r455", "r461", "r467", "r471", "r476", "r580", "r614", "r615", "r616", "r617", "r618", "r619" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r530" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r530" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r185", "r187", "r188", "r189", "r231", "r337", "r373", "r391", "r392", "r448", "r449", "r450", "r451", "r452", "r454", "r455", "r461", "r467", "r471", "r476", "r580", "r614", "r615", "r616", "r617", "r618", "r619" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r549" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Institutional Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r581" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r557" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r531" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r72", "r73", "r74" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r66", "r74", "r86", "r94", "r105", "r108", "r112", "r123", "r132", "r136", "r137", "r138", "r139", "r142", "r143", "r150", "r159", "r163", "r167", "r169", "r173", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r295", "r301", "r369", "r420", "r440", "r441", "r460", "r485", "r578" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r89", "r90", "r91", "r93", "r130", "r131", "r134", "r135", "r144", "r145", "r175", "r176", "r274", "r275", "r276", "r290", "r292", "r296", "r297", "r298", "r302", "r303", "r304", "r315", "r316", "r321", "r339", "r340", "r341", "r377", "r378", "r379", "r380", "r381" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "inkt_NewIntercompanyServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "NewIntercompanyServiceAgreementMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Intercompany Service Agreement", "label": "New Intercompany Service Agreement [Member]", "documentation": "New Intercompany Service Agreement." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r530" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r500", "r511", "r521", "r538", "r546" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r528" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r527" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r538" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r557" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r557" ] }, "inkt_NonVestedSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "NonVestedSharesMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Vested Shares", "label": "Non Vested Shares [Member]", "documentation": "Non-vested shares." } } }, "auth_ref": [] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of note", "label": "Notes Payable, Fair Value Disclosure", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": [ "r17" ] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficersCompensation", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold", "terseLabel": "Compensation paid", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r569" ] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses from transactions with related party", "label": "Operating Costs and Expenses", "totalLabel": "Operating Costs and Expenses, Total", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r159", "r163", "r167", "r169", "r460" ] }, "us-gaap_OperatingIncomeLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLossMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses", "label": "Operating Income (Loss) [Member]", "documentation": "Primary financial statement caption encompassing operating income (loss)." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r18" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r103", "r475" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "terseLabel": "Foreign currency translation gain (loss)", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r9", "r12", "r106", "r109", "r113", "r306", "r307", "r312", "r354", "r370", "r566", "r567" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "inkt_OtherIncomeExpenseNetMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "OtherIncomeExpenseNetMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income (Expense), Net", "label": "Other Income Expense Net [Member]", "documentation": "Other Income (Expense), Net." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities", "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r18", "r475" ] }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "inkt_OtherLiabilitiesCurrentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "OtherLiabilitiesCurrentLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities Current [Line Items]", "label": "Other Liabilities Current [Line Items]", "documentation": "Other liabilities, current." } } }, "auth_ref": [] }, "inkt_OtherLiabilitiesCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "OtherLiabilitiesCurrentTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities Current [Table]", "label": "Other Liabilities Current [Table]", "documentation": "Other liabilities, current." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Due to related parties", "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r22" ] }, "us-gaap_OtherLiabilityNoncurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilityNoncurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Liability, Noncurrent, Related and Nonrelated Party Status [Extensible Enumeration]", "documentation": "Indicates related and nonrelated party status for liability classified as other and noncurrent." } } }, "auth_ref": [ "r100", "r199", "r326", "r572" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r70" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net:", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r530" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r498", "r509", "r519", "r544" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r501", "r512", "r522", "r547" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r501", "r512", "r522", "r547" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r526" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r71" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r529" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r529" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r528" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r538" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r531" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r527" ] }, "inkt_PercentageOfComputationOfInterest": { "xbrltype": "percentItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PercentageOfComputationOfInterest", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of computation of interest", "label": "Percentage Of Computation Of Interest", "documentation": "Percentage of computation of interest." } } }, "auth_ref": [] }, "inkt_PercentageOfPerSharePriceOfEquitySecuritiesSoldInQualifiedFinancing": { "xbrltype": "percentItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PercentageOfPerSharePriceOfEquitySecuritiesSoldInQualifiedFinancing", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of per share price of equity securities sold in qualified financing", "label": "Percentage of Per Share Price of Equity Securities Sold in Qualified Financing", "documentation": "Percentage of per share price of equity securities sold in qualified financing." } } }, "auth_ref": [] }, "inkt_PercentageOfServiceCost": { "xbrltype": "percentItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PercentageOfServiceCost", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of service cost", "label": "Percentage Of Service Cost", "documentation": "Percentage of service cost." } } }, "auth_ref": [] }, "inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering": { "xbrltype": "percentItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PercentageValueOfCommonStockSoldInInitialPublicOffering", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage value of common stock sold in initial public offering", "label": "Percentage Value Of Common Stock Sold In Initial Public Offering", "documentation": "Percentage value of common stock sold in initial public offering." } } }, "auth_ref": [] }, "inkt_PeriodForBreachOfPaymentObligations": { "xbrltype": "durationItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PeriodForBreachOfPaymentObligations", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period for breach of payment obligations", "label": "Period For Breach Of Payment Obligations", "documentation": "Period for breach of payment obligations." } } }, "auth_ref": [] }, "inkt_PeriodOfLicenseAgreement": { "xbrltype": "durationItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PeriodOfLicenseAgreement", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of license agreement", "label": "Period Of License Agreement", "documentation": "Period of license agreement." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Prepaid Expense, Current, Total", "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r102", "r178", "r179", "r457" ] }, "inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ProceedsFromEmployeeStockPurchasesAndOptionExercises", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from employee stock purchases and option exercises.", "label": "Proceeds From Employee Stock Purchases And Option Exercises", "terseLabel": "Proceeds from employee stock purchases and option exercises" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate purchase price, net of offering expenses", "terseLabel": "Additional funding", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "inkt_ProceedsFromIssuanceOfRelatedPartyNote": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ProceedsFromIssuanceOfRelatedPartyNote", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of related party note", "label": "Proceeds from issuance of related party note", "documentation": "Proceeds from issuance of related party note." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r94", "r105", "r108", "r117", "r123", "r132", "r142", "r143", "r159", "r163", "r167", "r169", "r173", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r278", "r281", "r282", "r295", "r301", "r357", "r368", "r388", "r420", "r440", "r441", "r460", "r473", "r474", "r486", "r568", "r578" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, net of accumulated depreciation of $545,095 and $495,638 at March 31, 2024 and December 31, 2023, respectively", "totalLabel": "Property, Plant and Equipment, Net, Total", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r358", "r367", "r475" ] }, "inkt_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PurchaseAgreementMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Agreement", "label": "Purchase Agreement [Member]", "documentation": "Purchase agreement." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": [ "r57", "r84" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r57", "r84" ] }, "inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PurchaseOfTreasurySharesToSatisfyTaxWithholdings", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of treasury shares to satisfy tax withholdings", "label": "Purchase Of Treasury Shares To Satisfy Tax Withholdings", "documentation": "Purchase of treasury shares to satisfy tax withholdings." } } }, "auth_ref": [] }, "inkt_PurchasesOfPlantAndEquipmentInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "PurchasesOfPlantAndEquipmentInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of plant and equipment in accounts payable and accrued liabilities", "label": "Purchases Of Plant And Equipment In Accounts Payable And Accrued Liabilities", "documentation": "Purchases of plant and equipment in accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r526" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r526" ] }, "inkt_QualifiedFinancingTerms": { "xbrltype": "stringItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "QualifiedFinancingTerms", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualified financing terms", "label": "Qualified Financing Terms", "documentation": "Qualified financing terms." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r185", "r187", "r188", "r189", "r223", "r231", "r258", "r259", "r260", "r336", "r337", "r373", "r391", "r392", "r448", "r449", "r450", "r451", "r452", "r454", "r455", "r461", "r467", "r471", "r476", "r479", "r577", "r580", "r615", "r616", "r617", "r618", "r619" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r185", "r187", "r188", "r189", "r223", "r231", "r258", "r259", "r260", "r336", "r337", "r373", "r391", "r392", "r448", "r449", "r450", "r451", "r452", "r454", "r455", "r461", "r467", "r471", "r476", "r479", "r577", "r580", "r615", "r616", "r617", "r618", "r619" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r493", "r504", "r514", "r539" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r230", "r325", "r326", "r394", "r395", "r396", "r397", "r398", "r417", "r419", "r447" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r124", "r125", "r325", "r326", "r327", "r328", "r394", "r395", "r396", "r397", "r398", "r417", "r419", "r447" ] }, "inkt_RelatedPartyNote": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "RelatedPartyNote", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Related party note", "label": "Related party note", "documentation": "Related party note." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r325", "r326", "r611" ] }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDescriptionOfTransaction", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, description", "label": "Related Party Transaction, Description of Transaction", "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates." } } }, "auth_ref": [ "r88", "r100", "r317", "r318", "r319", "r324" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r423", "r424", "r427" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r230", "r325", "r326", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r394", "r395", "r396", "r397", "r398", "r417", "r419", "r447", "r611" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r322", "r323", "r324", "r326", "r329", "r385", "r386", "r387", "r425", "r426", "r427", "r445", "r446" ] }, "inkt_RepayableAdvanceReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "RepayableAdvanceReceived", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayable advance received", "label": "Repayable Advance Received", "documentation": "Repayable advance received." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Agreement", "label": "Research and Development Arrangement [Member]", "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r54", "r271", "r620" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "inkt_ResearchServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ResearchServicesMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Services", "label": "Research Services [Member]", "documentation": "Research Services." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r494", "r505", "r515", "r540" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r495", "r506", "r516", "r541" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r502", "r513", "r523", "r548" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r97" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r61", "r79", "r364", "r377", "r381", "r384", "r401", "r475" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r92", "r127", "r128", "r129", "r133", "r141", "r143", "r174", "r177", "r267", "r268", "r269", "r272", "r273", "r285", "r287", "r288", "r291", "r293", "r374", "r376", "r389", "r624" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r160", "r161", "r162", "r165", "r166", "r170", "r171", "r172", "r221", "r222", "r338" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r557" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r557" ] }, "us-gaap_SalariesWagesAndOfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesWagesAndOfficersCompensation", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation paid", "label": "Salary and Wage, Excluding Cost of Good and Service Sold", "totalLabel": "Salary and Wage, Excluding Cost of Good and Service Sold, Total", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate number of shares issued and sold", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price per share", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockTransactionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockTransactionDate", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, transaction date", "label": "Sale of Stock, Transaction Date", "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accrued liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Anti-dilutive Securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]", "label": "Schedule of Cash and Cash Equivalents [Table]", "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share-based Compensation Expense", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Non-vested Stock Activity", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r50", "r51", "r423", "r424", "r427" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r233", "r234", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r41" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r488" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r490" ] }, "inkt_ServiceAgreementNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "ServiceAgreementNoticePeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service agreement notice period", "label": "Service Agreement Notice Period", "documentation": "Service agreement notice period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option, vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r472" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Nonvested Shares, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r252" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r252" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Nonvested Shares, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r250" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r250" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested Shares, Outstanding at Beginning Balance", "periodEndLabel": "Nonvested Shares, Outstanding at Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r247", "r248" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at Beginning Balance, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at Ending Balance, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r247", "r248" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Nonvested Shares, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r251" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r251" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r233", "r234", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Exercisable at March 31, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r241" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at March 31, 2024, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r241" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r246" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r245" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Number of shares options, granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r243" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant-date fair values of options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r253" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at March 31, 2024, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r39" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options, Outstanding at Beginning Balance", "periodEndLabel": "Options, Outstanding at Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r239", "r240" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at Beginning Balance, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at Ending Balance, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r239", "r240" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at March 31, 2024, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r255" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Vested or expected to vest at March 31, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r255" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at March 31, 2024, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r255" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option grants, term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award", "documentation": "Description of terms of award under share-based payment arrangement." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r244" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r246" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r245" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r243" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at March 31, 2024, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r39" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at March 31, 2024, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r39" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at March 31, 2024, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r80" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at March 31, 2024, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r255" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance, Shares", "periodEndLabel": "Ending Balance, Shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares issued, withheld to cover taxes", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r75", "r122" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r24", "r92", "r110", "r111", "r112", "r127", "r128", "r129", "r133", "r141", "r143", "r158", "r174", "r177", "r220", "r267", "r268", "r269", "r272", "r273", "r285", "r286", "r287", "r288", "r289", "r291", "r293", "r306", "r308", "r309", "r310", "r311", "r312", "r320", "r374", "r375", "r376", "r389", "r442" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r127", "r128", "r129", "r158", "r338", "r382", "r390", "r393", "r394", "r395", "r396", "r397", "r398", "r400", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r417", "r419", "r421", "r422", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r480" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r127", "r128", "r129", "r158", "r338", "r382", "r390", "r393", "r394", "r395", "r396", "r397", "r398", "r400", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r413", "r414", "r415", "r416", "r417", "r419", "r421", "r422", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r480" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r497", "r508", "r518", "r543" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, $0.00001 par value, for payment of certain employee bonuses", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r29", "r30", "r31" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for employee bonuses, shares", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "verboseLabel": "Shares issued, payment for employee bonuses", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes": { "xbrltype": "sharesItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period, shares, employee benefit plan net of shares withheld for taxes.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan Net of Shares Withheld for Taxes", "terseLabel": "Shares issued, payment for employee bonuses, net of shares withheld for taxes" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Number of shares issued", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r9", "r58", "r59", "r79" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial public offering, net of offering costs, shares", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r58", "r59", "r79", "r383", "r442", "r453" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeiture of restricted stock, shares", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "documentation": "Number of shares related to Restricted Stock Award forfeited during the period." } } }, "auth_ref": [ "r9", "r58", "r59", "r79" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of nonvested shares, Shares", "verboseLabel": "Shares issued, vesting of non-vested stock", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r9", "r79" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Options, Exercised", "terseLabel": "Option exercises, Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "verboseLabel": "Stock option exercises", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r58", "r59", "r79", "r244" ] }, "inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan": { "xbrltype": "sharesItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised and employee stock purchase plan.", "label": "Stock Issued During Period Shares Stock Options Exercised And Employee Stock Purchase Plan", "terseLabel": "Exercise of stock options and employee share purchases, Shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for employee bonuses", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeiture of restricted stock", "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period." } } }, "auth_ref": [ "r9", "r58", "r59", "r79" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of nonvested shares", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r9", "r58", "r59", "r79" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r24", "r79" ] }, "inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised and employee stock purchase plan.", "label": "Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan", "terseLabel": "Exercise of stock options and employee share purchases" } } }, "auth_ref": [] }, "inkt_StockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "StockPurchaseAgreementMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Purchase Agreement", "label": "Stock Purchase Agreement [Member]", "documentation": "Stock Purchase Agreement." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share retirement, Shares", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r9", "r58", "r59", "r79" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r62", "r63", "r76", "r402", "r418", "r443", "r444", "r475", "r487", "r571", "r576", "r610", "r624" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS' DEFICIT" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r313", "r331" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r313", "r331" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r313", "r331" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r313", "r331" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureBusinessAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r313", "r331" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r330", "r332" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r537" ] }, "inkt_TerminateLicenseAgreementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "TerminateLicenseAgreementPeriod", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terminate license agreement period", "label": "Terminate License Agreement Period", "documentation": "Terminate license agreement period." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r529" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r536" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r556" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r558" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r559" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r560" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r558" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r558" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r561" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r559" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r38" ] }, "inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Issuance of shares for employee bonus, treasury shares", "label": "Treasury Stock Issued During Period Shares Employee Benefit Plan", "documentation": "Treasury stock issued during period shares employee benefit plan." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement of treasury shares", "label": "Treasury Stock, Retired, Cost Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": [ "r9", "r37", "r59" ] }, "us-gaap_TreasuryStockSharesRetired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesRetired", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement of treasury shares, share", "label": "Treasury Stock, Shares, Retired", "documentation": "Number of shares of common and preferred stock retired from treasury during the period." } } }, "auth_ref": [ "r9", "r59", "r79" ] }, "inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "2021 Employee Stock Purchase Plan.", "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r277" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r555" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares outstanding, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r148", "r153" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted average number of common shares outstanding, basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r147", "r153" ] }, "inkt_WolfGreenfieldSachsPCMember": { "xbrltype": "domainItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "WolfGreenfieldSachsPCMember", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Wolf, Greenfield & Sachs, P.C.", "label": "Wolf, Greenfield & Sachs, P.C. [Member]", "terseLabel": "Wolf, Greenfield & Sachs, P.C." } } }, "auth_ref": [] }, "inkt_WorkOrderReceivedFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://minktherapeutics.com/20240331", "localname": "WorkOrderReceivedFromRelatedParty", "crdr": "debit", "presentation": [ "http://minktherapeutics.com/20240331/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work order received from related party", "label": "Work Order Received From Related Party", "documentation": "Work order received from related party." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20,22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450-20/tableOfContent" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450-30/tableOfContent" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-7" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 52 0000950170-24-059081-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-059081-xbrl.zip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end XML 54 inkt-20240331_htm.xml IDEA: XBRL DOCUMENT 0001840229 2023-01-01 2023-03-31 0001840229 us-gaap:ResearchAndDevelopmentArrangementMember 2023-12-31 0001840229 us-gaap:RetainedEarningsMember 2022-12-31 0001840229 us-gaap:ResearchAndDevelopmentExpenseMember inkt:AtlantClinicalLtdMember 2023-01-01 2023-03-31 0001840229 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001840229 us-gaap:ResearchAndDevelopmentArrangementMember 2024-03-31 0001840229 inkt:OtherIncomeExpenseNetMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-01-01 2022-12-31 0001840229 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001840229 inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0001840229 inkt:NewIntercompanyServiceAgreementMember inkt:AgenusIncMember 2024-01-01 2024-03-31 0001840229 inkt:ResearchServicesMember inkt:AgenusIncMember 2024-01-01 2024-03-31 0001840229 us-gaap:ResearchAndDevelopmentExpenseMember inkt:AtlantClinicalLtdMember 2024-01-01 2024-03-31 0001840229 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001840229 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001840229 inkt:AgenusIncMember 2024-01-01 2024-03-31 0001840229 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001840229 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001840229 2024-05-10 0001840229 us-gaap:RetainedEarningsMember 2024-03-31 0001840229 us-gaap:SubsequentEventMember inkt:StockPurchaseAgreementMember 2024-05-13 2024-05-13 0001840229 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001840229 inkt:NonVestedSharesMember 2023-01-01 2023-03-31 0001840229 us-gaap:CommonStockMember 2023-12-31 0001840229 us-gaap:CommonStockMember 2024-03-31 0001840229 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001840229 inkt:ConvertiblePromissoryNoteMember inkt:PurchaseAgreementMember inkt:AgenusIncMember 2024-03-31 0001840229 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001840229 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001840229 inkt:AgenusIncMember 2024-02-12 2024-02-12 0001840229 us-gaap:CommonStockMember 2023-03-31 0001840229 inkt:ConvertiblePromissoryNoteMember inkt:PurchaseAgreementMember inkt:AgenusIncMember 2024-02-12 2024-02-12 0001840229 inkt:BusinessServicesAndOccupancyCostsMember inkt:AgenusIncMember 2024-01-01 2024-03-31 0001840229 us-gaap:RetainedEarningsMember 2023-12-31 0001840229 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001840229 inkt:DrBuellMember 2023-01-01 2023-12-31 0001840229 inkt:AtlantClinicalLtdMember 2024-03-31 0001840229 us-gaap:RetainedEarningsMember 2023-03-31 0001840229 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001840229 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001840229 inkt:ConvertibleAffiliatedNoteMember 2024-03-31 0001840229 2023-12-31 0001840229 us-gaap:CommonStockMember 2022-12-31 0001840229 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001840229 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001840229 2024-01-01 2024-03-31 0001840229 inkt:WolfGreenfieldSachsPCMember 2024-01-01 2024-03-31 0001840229 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001840229 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001840229 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001840229 us-gaap:RelatedPartyMember 2024-03-31 0001840229 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001840229 us-gaap:MoneyMarketFundsMember 2024-03-31 0001840229 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001840229 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001840229 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001840229 2024-03-31 0001840229 inkt:ConvertiblePromissoryNoteMember inkt:PurchaseAgreementMember inkt:AgenusIncMember 2024-03-01 2024-03-31 0001840229 inkt:NonVestedSharesMember 2024-01-01 2024-03-31 0001840229 inkt:IndividualServicesMember inkt:AgenusIncMember 2024-01-01 2024-03-31 0001840229 inkt:EmployeeBonusMember 2024-03-31 0001840229 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001840229 2023-03-31 0001840229 us-gaap:SubsequentEventMember 2024-05-13 2024-05-13 0001840229 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001840229 inkt:WolfGreenfieldSachsPCMember 2023-01-01 2023-03-31 0001840229 inkt:AtlantClinicalLtdMember 2022-01-01 2022-12-31 0001840229 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001840229 us-gaap:MoneyMarketFundsMember 2023-12-31 0001840229 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001840229 us-gaap:CommonStockMember us-gaap:SubsequentEventMember inkt:StockPurchaseAgreementMember 2024-05-13 2024-05-13 0001840229 2022-12-31 0001840229 inkt:AgenusIncMember 2023-01-01 2023-03-31 0001840229 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001840229 us-gaap:CommonStockMember us-gaap:SubsequentEventMember inkt:StockPurchaseAgreementMember 2024-05-13 0001840229 us-gaap:EmployeeStockOptionMember inkt:DrBuellMember 2023-01-01 2023-01-31 pure shares iso4217:USD shares iso4217:USD Q1 --12-31 false 0001840229 10-Q true 2024-03-31 2024 false 001-40908 MiNK Therapeutics, Inc. DE 82-2142067 149 Fifth Avenue Suite 500 New York NY 10010 212 994-8250 Common Stock, par value $0.00001 per share INKT NASDAQ Yes Yes Non-accelerated Filer true true false false 34727639 5817080 3367229 59394 53111 122477 177964 5998951 3598304 545095 495638 894992 953977 6893943 4552281 3486999 3911973 5282707 5037361 2338554 2453251 11108260 11402585 4211566 31600 48072 11841724 11157073 0.00001 0.00001 150000000 150000000 34699056 34599119 347 346 117296454 115772085 -385780 -430947 -137210228 -133396933 -20299207 -18055449 6893943 4552281 2549482 4193562 1280432 1660534 -3829914 -5854096 16619 168055 -3813295 -5686041 -0.11 -0.11 -0.17 -0.17 34642915 34642915 33966921 33966921 45167 -81335 -3768128 -5767376 34599119 346 115772085 -430947 -133396933 -18055449 -3813295 -3813295 45167 45167 792878 792878 22851 6896 6896 77086 1 -1 697563 697563 27033 27033 34699056 347 117296454 -385780 -137210228 -20299207 33856428 339 110829900 -292468 -110939074 -401303 -5686041 -5686041 -81335 -81335 99555 1 45495 45496 30413 887811 887811 33328 33328 476804 5 726260 163759 -379921 346344 -163759 -2 163759 379921 379919 34299441 343 112522794 -373803 -116625115 -4475781 -3813295 -5686041 53831 45686 592006 921139 4444 6349 10010 -424439 153919 324451 -549527 -727144 -758424 -2542207 -4366410 13500 -13500 5000000 6896 45496 379921 5006896 -334425 -14838 -29340 2449851 -4743675 3367229 19635725 5817080 14892050 5116 9961 23042 132590 792878 0.00001 726263 (1) Business and LiquidityMiNK Therapeutics, Inc. (“MiNK” or the “Company”) is a clinical stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (“iNKT”) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. MiNK’s proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, the Company believes that its approach represents a highly versatile application for therapeutic development in cancer and immune diseases. MiNK is leveraging its platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells. Since its inception in 2017, MiNK has incurred losses and expects to continue incurring operating losses and negative cash flows in the future until it is able to generate sales and profits. As of March 31, 2024, MiNK had an accumulated deficit of $137.2 million and cash and cash equivalents of $5.8 million.MiNK believes that its cash and cash equivalents balance, along with additional funding of $5.8 million received after quarter end (see Note 11), will be sufficient to satisfy its liquidity requirements for more than one year from when these financial statements were issued. Because MiNK is dependent on its parent, Agenus Inc. ("Agenus") for certain services and deferral of related payments as discussed in Note 7, and Agenus has recently disclosed the existence of a substantial doubt about its ability to continue as a going concern, in accordance with the relevant accounting guidance, the Company is also required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q. To support its liquidity requirements beyond one year from when these financial statements are issued the Company will require additional funding. The financial statements have been prepared on a basis that assumes MiNK will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.Management continually monitors MiNK's liquidity position and adjusts spending as needed in order to preserve liquidity. Potential sources of additional funding for the Company include: (1) seeking strategic partnerships and collaborations, as well as out-licensing opportunities, for the Company's portfolio programs and product candidates, (2) exploring avenues for securing non-dilutive financing, such as grants and collaborations to strengthen the Company's balance sheet, and (3) potential of equity or debt financing options. If additional funding is not obtained through these sources, Agenus has indicated a willingness to loan MiNK additional funds to finance its operations.MiNK’s product candidates are in various stages of development and additional expenditures will be required if the Company starts new trials, encounters delays in its programs, applies for regulatory approvals, continues development of its technologies, expands its operations, and/or brings its product candidates to market. The eventual total cost of each clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, and number of patients. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive, and uncertain. Because all of the Company’s programs are at an early stage of clinical development, the Company is unable to reliably estimate the cost of completing its research and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence. -137200000 5800000 5800000 (2) Significant Accounting Policies <div style="font-size:10pt;font-family:Times New Roman;">Fair Value OptionUnder the Fair Value Option subsection of ASC Subtopic 825-10, Financial Instruments – Overall, the Company has the irrevocable option to report most financial assets and liabilities at fair value on an instrument-by-instrument basis with changes in fair value reported in earnings. The Company has elected to report the related party note it issued to Agenus on February 12, 2024 (the “Note”) at fair value. The fair value of the Note is determined on a scenario based present value methodology. The outstanding principal amount of the Note was $5.0 million at March 31, 2024.</div>Other PoliciesThe Company’s remaining significant accounting policies are disclosed in the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 21, 2024. Since the date of those financial statements there have been no changes, other than the fair value option policy defined above, to the Company’s significant accounting policies. Financial Statement PreparationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of the Company’s management, the condensed consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. All significant intercompany transactions and accounts have been eliminated in consolidation. Operating results for the three months ended March 31, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.For the Company’s foreign subsidiaries, the local currency is the functional currency. Assets and liabilities of its foreign subsidiaries are translated into U.S. dollars using rates in effect at the balance sheet date while expenses are translated into U.S. dollars using average exchange rates during the period. The cumulative translation adjustment resulting from changes in exchange rates are included in the condensed consolidated balance sheets as a component of accumulated other comprehensive income (loss) in total stockholders’ deficit. Fair Value OptionUnder the Fair Value Option subsection of ASC Subtopic 825-10, Financial Instruments – Overall, the Company has the irrevocable option to report most financial assets and liabilities at fair value on an instrument-by-instrument basis with changes in fair value reported in earnings. The Company has elected to report the related party note it issued to Agenus on February 12, 2024 (the “Note”) at fair value. The fair value of the Note is determined on a scenario based present value methodology. The outstanding principal amount of the Note was $5.0 million at March 31, 2024. 5000000 (3) Net Loss Per Share Basic loss per common share is calculated by dividing the net loss by the weighted average number of common shares outstanding. Diluted loss per common share is calculated by dividing net loss by the weighted average number of common shares outstanding plus the dilutive effect of outstanding instruments such as stock options. Because the Company reported a net loss for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of March 31, 2024 and 2023, as they would be anti-dilutive: <div style="font-size:12pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.093%;"></td> <td style="width:1.58%;"></td> <td style="width:1%;"></td> <td style="width:12.863%;"></td> <td style="width:1%;"></td> <td style="width:1.58%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Three Months Ended March 31,</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">2024</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">2023</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;">Stock options</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">8,246,769</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">6,720,366</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;">Non-vested shares</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">781,893</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">885,756</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table></div> Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of March 31, 2024 and 2023, as they would be anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.093%;"></td> <td style="width:1.58%;"></td> <td style="width:1%;"></td> <td style="width:12.863%;"></td> <td style="width:1%;"></td> <td style="width:1.58%;"></td> <td style="width:1%;"></td> <td style="width:12.883%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Three Months Ended March 31,</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">2024</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">2023</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;">Stock options</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">8,246,769</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">6,720,366</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;">Non-vested shares</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">781,893</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">885,756</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 8246769 6720366 781893 885756 (4) Cash and Cash Equivalents <div style="font-size:10pt;font-family:Times New Roman;">Cash equivalents consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:28.894%;"></td> <td style="width:1.86%;"></td> <td style="width:1%;"></td> <td style="width:13.917%;"></td> <td style="width:1%;"></td> <td style="width:1.86%;"></td> <td style="width:1%;"></td> <td style="width:13.917%;"></td> <td style="width:1%;"></td> <td style="width:1.86%;"></td> <td style="width:1%;"></td> <td style="width:13.917%;"></td> <td style="width:1%;"></td> <td style="width:1.86%;"></td> <td style="width:1%;"></td> <td style="width:13.917%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">March 31, 2024</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">December 31, 2023</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Cost</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Estimated Fair Value</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Cost</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Estimated Fair Value</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Institutional money market funds</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">5,424</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">5,424</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,899</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,899</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table></div> Cash equivalents consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:28.894%;"></td> <td style="width:1.86%;"></td> <td style="width:1%;"></td> <td style="width:13.917%;"></td> <td style="width:1%;"></td> <td style="width:1.86%;"></td> <td style="width:1%;"></td> <td style="width:13.917%;"></td> <td style="width:1%;"></td> <td style="width:1.86%;"></td> <td style="width:1%;"></td> <td style="width:13.917%;"></td> <td style="width:1%;"></td> <td style="width:1.86%;"></td> <td style="width:1%;"></td> <td style="width:13.917%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">March 31, 2024</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">December 31, 2023</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Cost</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Estimated Fair Value</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Cost</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Estimated Fair Value</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Institutional money market funds</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">5,424</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">5,424</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,899</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,899</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 5424000 5424000 2899000 2899000 (5) Accrued and Other Current Liabilities <div style="font-size:12pt;font-family:Times New Roman;">Accrued liabilities consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">March 31, 2024</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">December 31, 2023</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Payroll</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,067</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,831</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Professional fees</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">492</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">398</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Research services</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">294</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">302</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Contract manufacturing costs</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,430</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,430</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Other</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">—</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">76</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">5,283</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">5,037</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table></div> Other current liabilities of $2.3 million as of both March 31, 2024 and December 31, 2023, represent the advance received under the Company’s research and development agreement with the Belgium Walloon Region Government (“Walloon Region”). In 2022, the Company received notice that the Walloon Region had obtained a default judgment seeking repayment of approximately $2.3 million of the advance based upon the Company allegedly not providing required notification that research and operations in the region were discontinued. Accrued liabilities consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">March 31, 2024</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">December 31, 2023</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Payroll</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,067</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,831</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Professional fees</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">492</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">398</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Research services</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">294</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">302</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Contract manufacturing costs</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,430</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2,430</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Other</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">—</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">76</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">5,283</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">5,037</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 2067000 1831000 492000 398000 294000 302000 2430000 2430000 76000 5283000 5037000 2300000 2300000 2300000 (6) Share-based Compensation Plans The Company primarily uses the Black-Scholes option pricing model to value options granted to employees and non-employees, as well as options granted to members of the Company’s Board of Directors. All stock option grants have 10-year terms and generally vest ratably over a 3 or 4-year period. <div style="font-size:12pt;font-family:Times New Roman;">A summary of option activity for the three-month period ended March 31, 2024 is presented below: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.869%;"></td> <td style="width:1.56%;"></td> <td style="width:1%;"></td> <td style="width:11.722%;"></td> <td style="width:1%;"></td> <td style="width:2.04%;"></td> <td style="width:1%;"></td> <td style="width:7.161%;"></td> <td style="width:1%;"></td> <td style="width:1.56%;"></td> <td style="width:1%;"></td> <td style="width:7.802%;"></td> <td style="width:1%;"></td> <td style="width:2.04%;"></td> <td style="width:1%;"></td> <td style="width:11.242%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Options</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Weighted Average Exercise Price</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Weighted Average Remaining Contractual Term (in years)</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Aggregate Intrinsic Value</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Outstanding at December 31, 2023</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">6,945,716</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2.03</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Granted</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,346,997</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">0.87</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Exercised</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">(15,469</td> <td style="white-space:nowrap;vertical-align:bottom;">)</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">0.01</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Forfeited</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">(30,262</td> <td style="white-space:nowrap;vertical-align:bottom;">)</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.72</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Expired</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">(213</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">)</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2.28</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Outstanding at March 31, 2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">8,246,769</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.85</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.51</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,926,229</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Vested or expected to vest at March 31, 2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">8,246,769</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.85</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.51</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,926,229</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Exercisable at March 31, 2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">4,534,989</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.58</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">6.55</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,875,043</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table></div> The weighted average grant-date fair values of options granted during the three months ended March 31, 2024 and 2023 were $0.69 and $1.74, respectively. During the three months ended March 31, 2024 and 2023, all options were granted with exercise prices equal to the market value of the underlying shares of common stock on the grant date. As of March 31, 2024, there was $3.0 million of unrecognized share-based compensation expense related to stock options granted to employees, consultants and directors which, if all milestones are achieved on outstanding performance based awards, will be recognized over a weighted average period of 1.8 years. For awards with performance conditions, expense is recognized if the underlying performance conditions are deemed probable of achievement. <div style="font-size:12pt;font-family:Times New Roman;">A summary of non-vested stock activity for the three-month period ended March 31, 2024 is presented below: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.2%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:18.22%;"></td> <td style="width:1%;"></td> <td style="width:2.16%;"></td> <td style="width:1%;"></td> <td style="width:17.74%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Nonvested Shares</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Weighted Average Grant Date Fair Value</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Outstanding at December 31, 2023</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">789,503</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.18</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Granted</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">69,476</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">0.95</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Vested</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">(77,086</td> <td style="white-space:nowrap;vertical-align:bottom;">)</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.04</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Forfeited</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">—</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Outstanding at March 31, 2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">781,893</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.17</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table></div> As of March 31, 2024, there was $0.8 million of unrecognized share-based compensation expense related to these non-vested shares which will be recognized over a weighted average period of 4.4 years.During the three months ended March 31, 2024, 7,382 shares were issued under the 2021 Employee Stock Purchase Plan, 15,469 shares were issued as a result of stock option exercises and 77,086 shares were issued as a result of the vesting of non-vested stock.Stock based compensation expense also includes expense related to awards to employees of the Company from the Agenus 2019 Equity Incentive Plan. The impact on the Company’s results of operations from share-based compensation for the three months ended March 31, 2024 and 2023, was as follows (in thousands): <div style="font-size:12pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.209%;"></td> <td style="width:2.26%;"></td> <td style="width:1%;"></td> <td style="width:18.636%;"></td> <td style="width:1%;"></td> <td style="width:2.26%;"></td> <td style="width:1%;"></td> <td style="width:18.636%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Three Months Ended March 31,</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">2024</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">2023</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Research and development</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">122</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">141</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">General and administrative</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">603</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">780</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Total share-based compensation expense</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">725</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">921</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table></div> 10-year P3Y P4Y A summary of option activity for the three-month period ended March 31, 2024 is presented below: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.869%;"></td> <td style="width:1.56%;"></td> <td style="width:1%;"></td> <td style="width:11.722%;"></td> <td style="width:1%;"></td> <td style="width:2.04%;"></td> <td style="width:1%;"></td> <td style="width:7.161%;"></td> <td style="width:1%;"></td> <td style="width:1.56%;"></td> <td style="width:1%;"></td> <td style="width:7.802%;"></td> <td style="width:1%;"></td> <td style="width:2.04%;"></td> <td style="width:1%;"></td> <td style="width:11.242%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Options</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Weighted Average Exercise Price</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Weighted Average Remaining Contractual Term (in years)</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Aggregate Intrinsic Value</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Outstanding at December 31, 2023</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">6,945,716</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2.03</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Granted</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,346,997</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">0.87</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Exercised</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">(15,469</td> <td style="white-space:nowrap;vertical-align:bottom;">)</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">0.01</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Forfeited</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">(30,262</td> <td style="white-space:nowrap;vertical-align:bottom;">)</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.72</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Expired</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">(213</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">)</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">2.28</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Outstanding at March 31, 2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">8,246,769</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.85</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.51</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,926,229</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Vested or expected to vest at March 31, 2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">8,246,769</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.85</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.51</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,926,229</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Exercisable at March 31, 2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">4,534,989</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.58</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">6.55</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1,875,043</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 6945716 2.03 1346997 0.87 15469 0.01 30262 1.72 213 2.28 8246769 1.85 P7Y6M3D 1926229 8246769 1.85 P7Y6M3D 1926229 4534989 1.58 P6Y6M18D 1875043 0.69 1.74 3000000 P1Y9M18D A summary of non-vested stock activity for the three-month period ended March 31, 2024 is presented below: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.2%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:18.22%;"></td> <td style="width:1%;"></td> <td style="width:2.16%;"></td> <td style="width:1%;"></td> <td style="width:17.74%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Nonvested Shares</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Weighted Average Grant Date Fair Value</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Outstanding at December 31, 2023</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">789,503</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.18</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Granted</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">69,476</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">0.95</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Vested</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">(77,086</td> <td style="white-space:nowrap;vertical-align:bottom;">)</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.04</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Forfeited</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">—</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Outstanding at March 31, 2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">781,893</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.17</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 789503 1.18 69476 0.95 77086 1.04 781893 1.17 800000 P4Y4M24D 7382 15469 77086 The impact on the Company’s results of operations from share-based compensation for the three months ended March 31, 2024 and 2023, was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.209%;"></td> <td style="width:2.26%;"></td> <td style="width:1%;"></td> <td style="width:18.636%;"></td> <td style="width:1%;"></td> <td style="width:2.26%;"></td> <td style="width:1%;"></td> <td style="width:18.636%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Three Months Ended March 31,</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">2024</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">2023</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Research and development</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">122</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">141</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">General and administrative</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">603</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">780</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;">Total share-based compensation expense</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">725</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">921</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 122000 141000 603000 780000 725000 921000 (7) Related Party Transactions Until the completion of its Initial Public Offering (“IPO”), the Company relied on Agenus for all of its working capital requirements. For the periods presented, certain of the Company’s operations were fully integrated with Agenus, including, but not limited to, corporate functions such as finance, human resources, information technology and certain legal functions. The Company’s consolidated financial statements reflect all costs of doing business related to these operations.In September 2021, the Company entered into an Intellectual Property Assignment and License Agreement with Agenus (the “New Assignment and License Agreement”), upon which the prior intercompany agreement between Agenus and MiNK was terminated. Pursuant to the New Assignment and License Agreement, Agenus assigned to the Company certain patent rights and know-how related to its iNKT cell platform, product candidates and other patents and know-how related to its business. In addition to the patent rights assigned to the Company by Agenus, the Company also received an exclusive, royalty-free, sublicensable license to research, develop, manufacture and commercialize certain licensed technology in the field. The New Assignment and License Agreement further provides for the Company to grant Agenus a field-limited, non-exclusive, royalty-free license under the assigned patent rights, subject to MiNK’s discretion and provided such access would not reasonably result in a disruption of planned MiNK activities. Agenus has also agreed to provide the Company with Agenus’ biological material upon written request in order for the Company to use such material in its development activities of a combination therapy. Agenus may withhold the transfer of biological material, including, but not limited to, checkpoint modulating antibodies, for various reasons, including if such transfer would reasonably result in a disruption of planned Agenus activities. For any materials Agenus does share with the Company, the parties have agreed to enter into a separate agreement governing the transfer and providing for joint ownership of the data. Agenus has agreed that during the full term of the New Assignment and License Agreement, and for three years thereafter, it will not develop, manufacture or commercialize an iNKT cell therapy, directly or indirectly by transferring such technology. The Company may terminate the New Assignment and License Agreement without cause upon 90 days’ prior written notice to Agenus. Either party may terminate if there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice.Effective April 1, 2022, the Company entered into an Amended and Restated Intercompany Services Agreement (the “New Intercompany Agreement”) with Agenus, which amended and restated the Intercompany General & Administrative Agreement between the Company and Agenus dated September 10, 2021 (the “Prior Intercompany Agreement”). Under the New Intercompany Agreement, Agenus provides the Company with certain general and administrative support, including, without limitation, financial, facilities management, human resources and information technology administrative support (the “Agenus Services”), and the Company and Agenus provide each other with certain research and development services (the “R&D Services”) and other support services, including legal and regulatory support (the “Shared Services”). The Company is required to pay 10% of Agenus’ costs related to the Agenus Services, and the costs of R&D Services are based upon pass-through costs related to such services plus an allocation of the costs of the employees performing the services. No payment will be due from either party for the Shared Services, provided that the services provided by each party are proportional in scope and volume. The Company is also entitled to use Agenus’ business offices and laboratory space and equipment in exchange for the Company contributing a proportionate payment for the use of such facilities and equipment, and the Company will be covered by certain Agenus insurance policies, subject to certain conditions, including the Company paying the cost of such coverage. Either party may terminate the New Intercompany Agreement upon 60 days’ prior written notice and individual services upon 30 days’ prior written notice. Allocated Agenus services primarily include payroll related expenses, facility costs, insurance and stock-based compensation, and are included in the accompanying financial statements based on certain estimates and allocations described above. Under the Prior Intercompany Agreement, the allocation methods primarily included time devoted to activities and headcount-based allocations. Agenus business services and occupancy costs were allocated to the Company based on the Company’s headcount as a percentage of Agenus’ and the Company was required to pay 105% of Agenus’ costs for these business services and occupancy costs. Research services were charged between the entities based on hours recorded by Agenus employees as time spent on specific projects, applied to hourly wage rates, and the Company paid 110% of Agenus’ costs for these research services. As such, these allocations may not be indicative of the actual amounts that would have been recorded had the Company operated as an independent, publicly traded company for the periods presented. Allocation of Agenus services, net of approximately $227,000 and $306,000 for the three months ended March 31, 2024 and 2023, respectively, is included in “Operating expenses” in the Company’s statement of operations and “Due to related parties,” of $11.8 million as of March 31, 2024, in the Company’s condensed consolidated balance sheet. Agenus has agreed to not require repayment of the related party balance prior to June 30, 2025.On February 12, 2024, the Company and Agenus entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million. The Purchase Agreement sets forth the terms and conditions, including representations and warranties, for the Company’s issuance and sale of the Note to Agenus.The Company may draw down on the principal amount of the Note from time to time with Agenus’s consent in any increment, either in the form of advancements or payments made by Agenus on the Company’s behalf. The Note carries an annual rate of interest rate of 2% (the “Interest Rate”) that accrues from the date funds are paid or advanced by Agenus to the Company. Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026. In the event of a qualified financing, the outstanding principal amount of the Note plus accrued and unpaid interest shall, at Agenus’ election, either be paid in full or converted into equity shares equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the equity securities sold in the qualified financing. Upon a change of control, the Company will pay Agenus an amount equal to (i) 1.5 times the principal then outstanding under the Note and (ii) the amount of accrued interest then outstanding immediately prior to the closing of such change of control. In March 2024, MiNK received $5.0 million from Agenus and the Note was fully drawn. As of March 31, 2024, the Note had a principal balance of $5.0 million and an accrued and unpaid interest balance of $4,444 and an effective interest rate of 17%.In January 2023, the Company's CEO (“Dr. Buell”), became an employee of Agenus in the role of Chairman of the Executive Counsel. As an employee of Agenus, Dr. Buell is paid $150,000 annually and was granted an option to acquire 37,500 shares of Agenus common stock that vest over a period of four years.In 2022, the Company entered into a Master Services Agreement with Atlant Clinical Ltd. (“Atlant”), a subsidiary of Agenus, to provide clinical trial support services to the Company, including an eTMF platform, medical monitoring and data manager services. The Company’s Audit and Finance Committee approved the engagement under its related-party transactions policy for up to $250,000 in services. These services are expected to be completed in 2024. As of March 31, 2024, the Company had entered into work orders with Atlant totaling approximately $167,000, plus out of pocket expenses which are to pass through to Company at cost. For the three months ended March 31, 2024 and 2023, approximately $13,000 and $22,000, respectively, related to these services is included in “Research and development” expense in the Company’s condensed consolidated statements of operations.Dr. Buell's spouse is a partner in the law firm of Wolf, Greenfield & Sachs, P.C. (“Wolf Greenfield”), which provided legal services to the Company during the periods ended March 31, 2024 and 2023, and continues to do so. For the three months ended March 31, 2024 and 2023, the Company expensed Wolf Greenfield fees totaling approximately $27,000 and $38,000, respectively. Dr. Buell’s spouse does not receive direct compensation from the fees paid to Wolf Greenfield by the Company and the fees paid by the Company to Wolf Greenfield in the period was an insignificant amount of Wolf Greenfield’s revenues. The Company’s Audit and Finance Committee approved these services under its related-party transactions policy. P3Y The Company may terminate the New Assignment and License Agreement without cause upon 90 days’ prior written notice to Agenus. Either party may terminate if there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice. P90D P45D 0.10 P60D P30D 1.05 1.10 227000 306000 11800000 5000000 0.02 Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026. In the event of a qualified financing, the outstanding principal amount of the Note plus accrued and unpaid interest shall, at Agenus’ election, either be paid in full or converted into equity shares equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the equity securities sold in the qualified financing. Upon a change of control, the Company will pay Agenus an amount equal to (i) 1.5 times the principal then outstanding under the Note and (ii) the amount of accrued interest then outstanding immediately prior to the closing of such change of control. 0.80 5000000 5000000 4444 0.17 150000 37500 250000 167000 13000 22000 27000 38000 (8) Fair Value Measurement The Company measures the Note at fair value. The fair value of the Note at March 31, 2024 was $4.2 million, based on the Level 2 valuation hierarchy of the fair value measurements standard using a scenario based present value methodology that was derived by evaluating the nature and terms of the Note and considering the prevailing economic and market conditions at the balance sheet date. As of March 31, 2024 the Note had a principal balance of $5.0 million. The difference between the determined fair value at the issuance of the Note and the proceeds received was recorded as additional paid-in capital in the Company’s condensed consolidated balance sheets as of March 31, 2024. 4200000 5000000 (9) Contingencies The Company may currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or liquidity, litigation is subject to inherent uncertainty and consumes both cash and management attention. (10) Recent Accounting Pronouncements <div style="font-size:10pt;font-family:Times New Roman;">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on the notes to its consolidated financial statements.No other new accounting pronouncement issued or effective during the three months ended March 31, 2024 had or is expected to have a material impact on the Company’s consolidated financial statements or disclosures. </div> Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on the notes to its consolidated financial statements.No other new accounting pronouncement issued or effective during the three months ended March 31, 2024 had or is expected to have a material impact on the Company’s consolidated financial statements or disclosures. (11) Subsequent Events On May 13, 2024, the Company entered into a Stock Purchase Agreement with a certain investor (the “Purchaser”), pursuant to which the Company issued and sold an aggregate of 4,640,000 shares of Common Stock (the “Common Shares”), at a purchase price of $1.25 per share. The aggregate purchase price paid by the Purchaser for the Common Shares will be approximately $5.8 million, net of offering expenses. The transaction is expected to close on May 14, 2024, subject to customary closing conditions. 2024-05-13 4640000 1.25 5800000 false false false false